

CURRICULUM VITAE

NAME Tomasz M. Beer

DATE August 31, 2012

PRESENT POSITION AND ADDRESS

Academic Rank: Grover C. Bagby Endowed Chair for Prostate Cancer Research
Professor of Medicine

Department/Division: Medicine/Hematology & Medical Oncology

II. EDUCATION

Undergraduate and Graduate (Include Year, Degree, and Institution):

1986 B.A. The Johns Hopkins University
1987 – 1988 Paul H. Nitze School of Advanced International Studies
Graduate training in International Relations
1991 M.D. The Johns Hopkins University School of Medicine

Postgraduate (Include Year, Degree, and Institution):

1991 – 1992 Intern in Medicine, Oregon Health Sciences University, Portland
1992 – 1994 Resident in Medicine, Oregon Health Sciences University, Portland
1995 – 1996 Chief Resident in Medicine, Oregon Health Sciences University, Portland
1996 – 1999 Fellow in Hematology and Medical Oncology,
Oregon Health Sciences University, Portland

Other – Additional Educational Activities Attended:

2005 The Foundation for Medical Excellence
“Health Care Leadership for the 21st Century – Institute One”
2005 The Foundation for Medical Excellence
“Health Care Leadership for the 21st Century – Institute Two”
2006 - 2007 OHSU Leadership Academy
2006 OHSU Clinical Service Excellence Training
2006 Real World Entrepreneurship
2007 Harvard School of Public Health: Leadership Development for
Physicians in Academic Health Centers

Certification:

1995 American Board of Internal Medicine
2010-Nov ABIM, Medical Oncology

Licenses:

1992 Oregon Medical License
1994 Washington Medical License

III. PROFESSIONAL EXPERIENCE

Academic (Include Year, Position, and Institution):

- 1999 – 2000 Instructor, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health Sciences University, Portland
- 2001 - 2004 Assistant Professor, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland
- 2004 - 2009 Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland
- 2007 Grover C. Bagby Endowed Chair for Prostate Cancer Research
OHSU Knight Cancer Institute, September 2007
- 2009 - Professor, Division of Hematology and Medical Oncology,
School of Medicine, Oregon Health & Science University, Portland

Administrative (Include Year, Position, and Institution):

- 2003 - 2004 Acting Head, Hormone and Reproductive Malignancies Program, OHSU
Cancer Institute
- 2003 - Director, Prostate Cancer Research Program, OHSU Cancer Institute
- 2004 - Leader, Prostate Cancer Focus Group, Solid Tumors Program, OHSU
Cancer Institute
- 2007 - Head, Section of Solid Tumor Oncology, Division of Hematology and
Medical Oncology, OHSU Department of Medicine
- 2009 - Deputy Director, OHSU Knight Cancer Institute

Other (Include Year, Position, and Institution):

- 1999 - Staff Physician, Portland VA Medical Center

IV. SCHOLARSHIP**Area(s) of Research/Scholarly Interest:**

- Clinical trials in prostate cancer
Preclinical investigation in prostate cancer
Genetic risk factors for prostate cancer

Faculty on Major Advisory Boards

- Clinical Trial Endpoints in Prostate Cancer, Baltimore, MD, May 2005

Awards

- 1983 – 1986 Beneficial Hodson Scholar, The Johns Hopkins University
- 1984 Alpha Epsilon Delta
- 1985 Tau Beta Pi
- 1986 Departmental and General Honors, The Johns Hopkins University
- 1994 Alpha Omega Alpha
- 1994 Resident Teaching Award
- 1998 N.L. Tartar Research Fellow
- 1999 Jean and Harold Grossman – American Cancer Society Cancer Research
Fellow
- 2003 Robert D. Goldman Award
- 2004 Fellow, American College of Physicians
- 2005 Best Doctors in America listing
- 2007 - 2008 Best Doctors in America listing

2008	Portland Magazine's "Top Docs '08" listing
2008	Castle Connolly Medical Ltd. America's Top Doctors listing
2008	Marquis Who's Who listing
2008	The Global Directory of WHO'S WHO listing
2008	America's Top Oncologists 2008 Edition
2008 – 2009	Cambridge Who's Who Among Executives and Professionals in Healthcare "Honors Edition" listing
2009	Marquis Who's Who in America listing, 63 rd Edition
2009	Castle Connolly Medical Ltd. America's Top Doctors for Cancer, 5 th Edition
2009	Castle Connolly Medical Ltd. America's Top Doctors, 9 th Edition
2009	The Global Directory of WHO'S WHO listing
2009	Guide to America's Top Oncologists, 2009 Edition
2009	OHSU Technology Innovation Award for Pulse Doses of Vitamin D and Analogues as Anticancer Therapy (Technology Licensed to Startup Onco-D Therapeutics)
2009 – 2010	Marquis Who's Who in Medicine and Healthcare, 7 th Edition
2009 – 2010	Best Doctors in America listing
2010	Marquis Who's Who in America listing, 64 th Edition
2010	2010 Man of the Year in Medicine & Healthcare, American Biographical Institute, Inc.
2010	Top 3 OHSU Technology Innovation Award for Pulse Doses of Vitamin D and Analogues as Anticancer Therapy (Licensed to Receptor Therapeutics)
2011	Marquis Who's Who in America listing, 65 th Edition
2011 – 2012	Marquis Who's Who in Science and Engineering listing, 11 th Edition

Patents:

US patent 6,521,608: Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders

Australian patent 762481 (32022/99): Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders

Applications filed:

Prevention of Thrombotic Disorders with Active Vitamin D Compounds of Mimics Thereof (US patent applications 11/482,111)

Estrogen administration for treating male cognitive dysfunction or improving male cognitive function (US patent application serial no. 60/533,693)

IRX5 inhibition as treatment for hyperproliferative disorders (US patent application serial no. 60/571,043)

Transdermal diethylstilbestrol for treating prostate cancer (US patent application serial no. 60/851,255)

Publications/Creative Work:

Peer-reviewed (Original Articles)

- 1) McWilliams JE, Evans AJ, Beer TM, Anderson PE, Cohen JI, Everts EC, Henner WD. Genetic Polymorphisms in Head and Neck Cancer Risk. *Head Neck*. 2000 Sep; 22(6):609-17.
- 2) Beer TM, Munar M, Henner WD. A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies: Pulse Dosing Permits Substantial Dose Escalation. *Cancer*. 2001 Jun; 91(12):2431-9.

- 3) Garzotto M and Beer TM. Syndrome of Inappropriate Anti-Diuretic Hormone Secretion: A Rare Complication of Prostate Cancer. *Journal of Urology* 166:1386, 2001.
- 4) Beer TM, Pierce WC, Lowe BA, and Henner WD. Phase II Study of Weekly Docetaxel in Symptomatic Androgen-Independent Prostate Cancer. *Annals of Oncology* 12: 1273-1279, 2001.
- 5) Henner WD, Evans AJ, Hough KM, E Harris, and Lowe BA, Beer TM, Association of Codon 72 Polymorphism of p53 with Lower Prostate Cancer Risk. *The Prostate* 49:263-266, 2001.
- 6) Beer TM, Evans AJ, Hough KM, Lowe BA, McWilliams JE, and Henner WD. Polymorphisms of *GSTP1* and Related Genes in Prostate Cancer Risk. *Prostate Cancer and Prostatic Diseases*, 5:22-27, 2002.
- 7) Hayes-Lattin BM, Kovach, PA, Henner WD, and Beer TM, Successful Treatment of Metastatic Hormone-Refractory Prostate Cancer with Malignant Pericardial Tamponade using Docetaxel. *Urology* 59:137, 2002.
- 8) Madison DL, Blizotes M, and Beer TM. Acute Estramustine-Induced Hypocalcemia Unmasking Severe Vitamin D Deficiency. *American Journal of Medicine*, 112:680-681,2002.
- 9) Lavelle M, Schuff KG, Keller FS, Binkert CA, O'Hara M, Fairfax CA, and Beer TM. Unilateral autonomous testicular testosterone production mimicking androgen-independent prostate cancer. *Journal of Urology*, 168:1098-99, 2002.
- 10) Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, and Henner WD. Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer. *Journal of Clinical Oncology*, 21:123-128, 2003.
- 11) Beer TM, Lemmon D, Lowe BA, Henner WD. High dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate cancer. *Cancer*, 97:1217-1224, 2003.
- 12) Rago RP, Einstein Jr AB, Lush III RM, Beer TM, Ko Y, Henner WD, Bublely G, Shepard RC, Chatta G, Unger P, Merica EA, Garg V, Harding MW, and Dalton WS. Safety and efficacy of the MDR inhibitor Incel™ (Biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone refractory prostate cancer. *Cancer Chemotherapy & Pharmacology*, 5:297-305, 2003.
- 13) Beer TM, Garzotto M, Eilers, KM, Lemmon D. Phase II Study of Abarelix-Depot in Androgen-Independent Prostate Cancer Progressing on GnRH Agonist Therapy. *Journal of Urology*, 169:1738-41, 2003.
- 14) Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, and Beer TM. A Comparison of CT scan to Transrectal Ultrasound-Measured Prostate Volume in Untreated Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, 57(1):29-32, 2003.
- 15) Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive Modeling for the Presence of Prostate Cancer Using Clinical, Laboratory and Ultrasound Parameters with PSA \leq 10 ng/ml. *Cancer*, 98:1417-22, 2003.
- 16) Beer TM, Berry W, Wersinger EM, and Bland LB. Weekly docetaxel in the elderly: a comparison of efficacy and toxicity in prostate cancer patients age 70 and older and younger than 70. *Clinical Prostate Cancer*, 2:167-172, 2003.
- 17) Beer TM, Morris CD, Montalto MA, McMurry M, Nyberg SE, and Henner WD. Simplified Assessment of Compliance with Dietary Calcium Restriction in Patients Treated with High Dose Calcitriol for Advanced Cancer. *Topics in Clinical Nutrition* 18(1):61-70, 2003.
- 18) Beer TM, Garzotto M, Henner WD, Eilers KM. Intermittent Chemotherapy in Metastatic Androgen-Independent Prostate Cancer. *Br J Cancer*, 89(6):968-70, 2003. (PMCID: PMC2376967)
- 19) Evans AJ, Henner WD, Eilers KM, Montalto MA, Wersinger EM, Andersen PE, Cohen JI, MD, Everts EC, McWilliams JE, Beer TM. Polymorphisms of *GSTT1* and Related Genes

- in Head and Neck Cancer Risk. *Head and Neck*, 26:63-70, 2004.
- 20) Beer TM, Garzotto M, Eilers KM, and Henner WD. Quality of life during treatment with Calcitriol Enhanced Docetaxel in Metastatic Androgen-Independent Prostate Cancer. *Cancer*, 100:758-63, 2004.
 - 21) Beer TM, Garzotto M, Eilers KM, Lemmon D, EM Wersinger. Targeting FSH in Androgen-Independent Prostate Cancer: Abarelix for Prostate Cancer Progressing after Orchiectomy. *Urology*, 63:342-347, 2004.
 - 22) El-Geneidi M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L, Klein T, and Beer TM. Delayed Therapy with Curative Intent in a Contemporary Prostate Cancer Watchful Waiting Cohort. *BJU International*, 93:510-515, 2004.
 - 23) Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, and Higano CS. Phase I Study of Weekly Docetaxel and Mitoxantrone prior to Prostatectomy in Patients with High Risk Localized Prostate Cancer. *Clinical Cancer Research*, 10:1306-1311, 2004.
 - 24) Tiffany NM, Wersinger EM, Garzotto M, and Beer TM. Imatinib mesylate and zoledronic acid in symptomatic androgen-independent prostate cancer. *Urology*, 63:934-939, 2004.
 - 25) Fromme EK, Eilers KM, Mori M, Hsieh YC, and Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison to patient-reported symptoms from the QLQ-C30. *Journal of Clinical Oncology*, 22:3485-90, 2004.
 - 26) Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple Cycles of Intermittent Chemotherapy in Metastatic Androgen-Independent Prostate Cancer. *Br J Cancer*: 91(8), 1425-1427, 2004. (PMCID: PMC2409932)
 - 27) Beer TM, Garzotto M, and Katovic NM. High Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer. *American Journal of Clinical Oncology*, 27: 535-541, 2004.
 - 28) Beer TM, Tangen C, Bland LB, Thompson IM, and Crawford ED. Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894. *Journal of Urology*, 172(6, Part 1 of 2):2213-2217, 2004.
 - 29) Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, and Garzotto M. Predictors of Delayed Cancer-Directed Intervention in Patients Who Choose Watchful Waiting for Localized Prostate Cancer in the PSA Era, *Oncology (Basel)*, 67:194-202, 2004.
 - 30) Beer TM, Myrthue A, Garzotto M, O'Hara MF, Chin R, Lowe BA, Montalto MA, Corless CL, and Henner WD. Randomized Study of High-Dose Pulse Calcitriol or Placebo Prior to Radical Prostatectomy. *Cancer Epidemiology Biomarkers and Prevention*, 13(12):2225-32, 2004.
 - 31) Vetto JT, Beer TM, Fidda N, Ham B, Jimenez-Lee R, and Schmidt W. Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate cancer. *Diagnostic Cytopathology*, 31(6):417-419, 2004.
 - 32) Bland LB, Garzotto M, DeLoughery TD, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, and Beer TM. Phase II Study of Transdermal Estrogen in Androgen-Independent Prostate Cancer. *Cancer*, 103:717-23, 2005.
 - 33) Wagner M, Garzotto M, Lemmon D, Eilers KM, and Beer TM. Prostate Specific Antigen Decline after GnRH Antagonist Withdrawal in Androgen Independent Prostate Cancer. *Urology*, 65(4):799, 2005
 - 34) Devi GR, Beer TM, Corless C, Arora V, Reddy MT, Weller D, and Iversen PL. *In vivo* Bioavailability and Pharmacokinetics of a *c-myc* Phosphorodiamidate Morpholino Antisense Oligomer, AVI4126, in Solid Tumors, *Clinical Cancer Research*, 11(10):3930-8, 2005.
 - 35) Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM and Garzotto M. Resistance of Prostate Cancer Cell Lines to COX-2 Inhibitor Treatment *Biochem Biophys Res Commun*, 332(3):800-7, 2005.

- 36) Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, Klein T, Mori M. Improved Detection of Prostate Cancer using Classification and Regression Tree (CART) Analysis. *J Clin Oncol*, 23(19):4322-9, 2005.
- 37) Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M and Garzotto M, Clinical Outcomes of Androgen Deprivation as Sole Therapy for Localized and Locally Advanced Prostate Cancer, *BJU International*, 96:503-507, 2005.
- 38) Stephenson RA, Mori M, Hsieh Y-C, Beer TM, and Potosky AL. Treatment of Erectile Dysfunction Following Treatment for Clinically Localized L. Prostate Cancer: Usage and Satisfaction Measures from the SEER Prostate Cancer Outcomes Study (PCOS). *Journal of Urology*, 174(2):646-50, 2005.
- 39) Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A. Statins and prostate cancer risk: a case-control study, *American Journal of Epidemiology*, 162(4):318-25, 2005.
- 40) Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, and Beer TM. High Dose Pulse Calcitriol, Docetaxel, and Estramustine in Androgen-Independent Prostate Cancer (AIPC): A Phase I/II Study. *Journal of Urology*, 174(3):888-92, 2005.
- 41) Beer TM, Javle M, Lam GN, Henner WD, and Trump DL. Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer, *Clinical Cancer Research*, 11(21):7794-9, 2005.
- 42) Garzotto M, Park Y, Mongoue-Tchokote S, Bledsoe J, Peters L, Blank BH, Austin D, Beer TM, Mori M. Recursive Partitioning for Risk Stratification in Men Undergoing Repeat Prostate Biopsies, *Cancer*, 104(9):1911-7, 2005.
- 43) Bussiere JR, Beer TM, Neiss MB, and Janowsky JS. Androgen Deprivation Impairs Memory in Older Men, *Behavioral Neuroscience*, 119(6):1429-37, 2005.
- 44) Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modifies memory in men, *Journal of Urology*, 175(1):130-5, 2006.
- 45) Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, and Beer TM. Effect of transdermal estrogen therapy levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. *Journal of Lipid Research*, 47(2):349-55, 2006.
- 46) Spurgeon S, Hsieh YC, Rivadinera A, Beer TM, Mori M, and Garzotto M. Classification and Regression Tree Analysis for the Prediction of Aggressive Prostate Cancer on Biopsy, *Journal of Urology*, 175(3):918-22, 2006.
- 47) Ganzini L, Beer TM, Brouns M, Mori M, Hsieh Y-C. Interest in Physician Assisted Suicide Among Oregon Cancer Patients, *The Journal of Clinical Ethics*, 17(1):27-38, 2006.
- 48) Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K. Effect of calcitriol on Prostate Specific Antigen (PSA) *in vitro* and in humans. *Clinical Cancer Research*, 12(9):2812-6, 2006
- 49) Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED Southwest Oncology Group Phase II Study of Arsenic Trioxide in Patients with Refractory Germ Cell Malignancies, *Cancer*, 106(12):2624-9, 2006.
- 50) Adams G, Mitchell A, Ravichandran R, Beer TM and Garzotto M. Metastatic adenocarcinoma of the prostate in a healing sternotomy site, *Urology*, 68(1):204.e13-5, 2006.
- 51) True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS. A Molecular Correlate to the Gleason Grading System for Prostate Adenocarcinoma, *Proc Natl Acad Sci U S A*. 103(29):10991-6, 2006. (PMCID: PMC1544162)
- 52) Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, Deloughery TG, Crawford

- ED. Prognostic Value of Hemoglobin Change After Initiation of Androgen Deprivations Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis Of SWOG 8894. *Cancer*, 107:489-96, 2006.
- 53) Ryan CW, Huo D, Demers LM, Beer TM, Lacerna L. Zoledronic Acid Initiated During the First Year of Androgen-Deprivation Therapy Increases Bone Mineral Density in Prostate Cancer Patients. *Journal of Urology*, 176(3):972-8, 2006.
 - 54) Ganzini L, Beer TM, Brouns MC Views on Physician-Assisted Suicide Among Family Members of Oregon Cancer Patients. *Journal of Pain and Symptom Management*, 32(3):230-6, 2006.
 - 55) Lycette JL, Luoh SW, Beer TM, and Deloughery T. Acute Bilateral Pulmonary Emboli Occurring While on Adjuvant Aromatase Inhibitor Therapy with Anastrozole – Case Report and Review of the Literature, *Breast Cancer Research and Treatment*, 99(3):249-55, 2006.
 - 56) Beer TM, Ryan C, Bhat G, Garnick M. Dose-escalated abarelix in Androgen-Independent Prostate Cancer: a Phase I Study. *Anti-Cancer Drugs*, 17(9):1075-9, 2006
 - 57) Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, Beer TM, Bauer DC, Zmuda JM, Orwoll ES. Prevalence, Severity and Health Correlates of Lower Urinary Tract Symptoms among Older Men: The MrOS Study. *Urology*, 68(4):804-9, 2006.
 - 58) Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Curd JG, Arroyo A, Clow FW. High dose calcitriol may reduce thrombosis in cancer patients. *British Journal of Hematology*, 135(3):392-4, 2006.
 - 59) Beer TM, Javle M, Ryan CW, Wong A, Lam GN, Henner WD, and Trump DL. Phase I study of Weekly DN-101, a New Formulation of Calcitriol, in Patients with Cancer. *Cancer Chemotherapy and Pharmacology*, 59(5):581-7, 2007.
 - 60) Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario V, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. *J Clin Oncol*, 20;25(6):669-74, 2007
 - 61) Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky A, and Beer TM. Predictors of Overall and Cancer-Free Survival in Patients with Localized Prostate Cancer Treated Initially with Androgen Suppressive Therapy: Results from the Prostate Cancer Outcomes Study. *Journal of Urology*, 177(4):1307-12, 2007.
 - 62) Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Sugar EA, Eisenberger MA. Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients after Radical Prostatectomy: a Multi-Institutional Pilot Study, *Journal of Urology*, 177(5):1777-81, 2007.
 - 63) Spurgeon SEF, Mongoue-Tchokote S, Collins L, Priest R, Hsieh Y-C, Peters LM, Beer TM, Mori M, Garzotto M Assessment of Prostate-Specific Antigen Doubling Time in the Prediction of Prostate Cancer on Needle Biopsy, *Urology*, 69(5):931-5, 2007.
 - 64) Beer TM, Bergenstock M, Birt K, and Higano CS. Darbepoetin administered every 4 weeks for anemia in advanced prostate cancer patients. *Clinical GU Cancer*, 5:329-33, 2007.
 - 65) Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy, *Urology*, 70(1):122-126, 2007.
 - 66) Lagunova Z, Porojnicu A, Dahlback A, Berg JP, Beer TM and Moan J. The prognosis of prostate cancer is dependent on season of diagnosis, *Prostate*, 67(12):1362-70, 2007.
 - 67) Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan

- CX, Drabkin HA, Crawford ED. Sorafenib with Interferon Alfa-2b as First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. *J Clin Oncol*, 25(22):3296-3301, 2007.
- 68) Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS. Molecular Alterations in Prostate Carcinomas that Associate with *In Vivo* Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15, *Clin Cancer Res*. 13(19):5825-5833, 2007.
- 69) Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL. Phase II Study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel, *Invest New Drugs*, 25(6):565-570, 2007.
- 70) Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer, *Cancer*, 110(5):996-1002, 2007.
- 71) Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, and Oh WK. A Phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel, *Cancer*. 2008 Feb;112(3):521-26.
- 72) Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD. Intermittent Chemotherapy in patients with Metastatic Androgen-Independent Prostate Cancer: Results from ASCENT, a Double-blinded, Randomized Comparison of High-dose Calcitriol Plus Docetaxel with Placebo Plus Docetaxel, *Cancer*. 2008 Jan;112(2):326-30.
- 73) Beer TM, Goldman B, Nichols CR, Petrylak DP, Agarwal M, Ryan CW, Crawford ED, Southwest Oncology Group Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium, *Clin GU Cancer*. 2008 Mar;6(1):36-9.
- 74) Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol*. 2008 Mar;26(7):1148-59.
- 75) Ciszewski A, Shackleton D, Beer TM. Long term remission of metastatic small cell carcinoma of the prostate, *Urology*.2008 Mar;71(3), 546.
- 76) Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN. C-Reactive Protein as a Prognostic Marker for Men with Androgen-Independent Prostate Cancer (AIPC): Results from the ASCENT Trial. *Cancer*. 2008 Jun;112(11):2377-83.
- 77) Myrthue A, Rademacher BL, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, Beer TM. The Iroquois Homeobox Gene 5 is a Novel 1,25-Dihydroxyvitamin D3 Target in Human Prostate Cancer. *Clin Cancer Res*. 2008 Jun;14(11):3562-70.
- 78) Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ Jr, Dakhil SR, Lara PN Jr, Drelichman A, Hussain MH, Crawford ED. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer (AIPC) previously treated with taxanes. *Clin GU Ca*. 2008 Sept;6(2):103-9.
- 79) Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM. Patient-Physician Disagreement About Performance Status Is Associated with Worse Survivorship in Patients with Advanced Cancer. *Cancer*. 2008 Oct;113(8):2205-14.
- 80) Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. A Phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen independent prostate cancer. *BJU Int*. 2008 Dec;102(11):1601-6.
- 81) Schnadig ID, Beer TM. Optimal timing of chemotherapy in androgen independent prostate cancer. *Urol Oncol*. 2009 Jan-Feb;27(1):97-100.

- 82) Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research, *Clin GU Cancer* 2009 Jan;7(1):51-7.
- 83) Farhat GN, Taioli E, Cauley JA, Zmuda JM, Orwoll E, Bauer DC, Wilt TJ, Hoffman AR, Beer TM, Shikany JM, Daniels N, Chan J, Fink HA, Barrett-Connor E, Parsons JK, Bunker CH. The Association of Bone Mineral Density with Prostate Cancer Risk in the Osteoporotic Fractures in Men (MrOS) Study. *Ca Epidemiol Biomark Prev.* 2009 Jan;18(1):148-54. (PMCID: PMC2651680)
- 84) Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM. Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies. *Clin Cancer Res.* 2009 May;15(9):3135-42. (PMCID: PMC2929837)
- 85) Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science.* 2009 May;324(5928):787-90. (PMCID: PMC2981508)
- 86) Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the Department of Defense Prostate Cancer Clinical Trials Consortium. *J Clin Oncol.* 2009 Jun;27(17):2772-8. (PMCID: PMC2698016)
- 87) Blanke CD, Beer TM, Todd K, Mori M, Stone M, Lopez C. Phase II Study of Calcitriol-Enhanced Docetaxel in Patients with Previously Untreated Metastatic or Locally Advanced Pancreatic Cancer. *Invest New Drugs.* 2009 Aug;27(4):374-8.
- 88) Taplin ME, Regan MM, Ko YJ, Bublely GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. *Clin Cancer Res.* 2009 Nov;15(22):7099-105.
- 89) Qian DZ, Rademacher BLS, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. *Prostate,* 2010 Mar;70(4):433-42. (PMCID: PMC2931415)
- 90) Garzotto M, Higano CS, O'Brien C, Rademacher BLS, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM. Phase I/II Study of Preoperative Docetaxel and Mitoxantrone for High-risk Prostate Cancer. *Cancer.* 2010 Apr; 116(7):1699-708. (PMCID: PMC2846994)
- 91) Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A Phase II study of Paclitaxel Poliglumex (PPX) in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. *Anti-Cancer Drugs.* 2010 Apr; 21(4):433-8.
- 92) O'Brien C, True LD, Higano CS, Rademacher BLS, Garzotto M, Beer TM. Histological changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. *Am J Clin Pathol.* 2010 Apr; 133(4):654-61. (PMCID: PMC3047497)
- 93) Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. *Cancer Res.* 2010 Apr; 70(8):3239-48. (PMCID: PMC2999007)

- 94) Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL. Antitumor Activity of MDV3100 in Castration-Resistant Prostate Cancer: a Phase I-2 Study. *Lancet*. 2010 Apr: 375(9724):1437-46. (PMCID: PMC2948179)
- 95) Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, Hoffman AR, Barrett-Connor E, Orwoll E, Beer TM. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. *Cancer Causes Control*. 2010 Aug: 21(8): 1297-303. (PMCID: PMC2903686)
- 96) Zhu ML, Horbinski C, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer. *Cancer Res*. 2010 Oct: 70(20): 7992-8002. (PMCID: PMC 2978028)
- 97) Beer TM, Benavides M, Emmons SL, Hayes M, Liu G, Garzotto M, Donovan D, Katovic N, Reeder C, Eilers K. Acupuncture for hot flashes in patients with prostate cancer. *Urology*. 2010 Nov: 76(5):1182-8. (PMCID: PMC2928879)
- 98) Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. *Cancer*. 2010 Dec: Epub ahead of print.
- 99) Barnett CM, Flamiatos JF, Beer TM. Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy. *Anticancer Res*. 2011 Mar: 31(3): 973-4.
- 100) Ryan CW, Vuky J, Chan JS, Chen Z, Beer TM, Nauman D. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. *Invest New Drugs*. 2011 Apr: 29(2): 374-9.
- 101) Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma. *Sci Transl Med*. 2011 Jun: 3(85): 85ra47. (PMCID: PMC3303496)
- 102) Beer TM, Bernstein GT, Corman JM, Glode M, Hall SJ, Poll W, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW. Randomized trial of autologous cellular immunotherapy with Sipuleucel-T in androgen dependent prostate cancer. *Clin Cancer Res*. 2011 Jul: 17(13): 4558-67.
- 103) Barnett CM, Beer TM. Prostate cancer and vitamin D: what does the evidence really suggest? *Urol Clin North Am*. 2011 Aug: 38(3): 333-42.
- 104) Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: efficacy and safety. *Eur Urol*. 2011 Aug: 60(2): 279-90.
- 105) Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. *Urol Oncol*. 2011 Aug: Epub ahead of print. (PMCID: PMC3227793)
- 106) Graff JN, Beer TM. Toward predictors of survival in castration-resistant prostate cancer. *Cancer*. 2011 Sep: 117(17): 3882-4.
- 107) Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, Qian DZ. HDAC4 protein regulates HIF1 α protein lysine acetylation and cancer cell response to hypoxia. *J Biol Chem*. 2011 Nov: 286(44): 38095-102. (PMCID: PMC3207467)

- 108) Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, Beer TM. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. *Urol Oncol*. 2012 Jan; 30(1): 33-7. (PMCID: PMC2894303)
- 109) Winters-Stone KM, Lyons KS, Nail LM, Beer TM. The exercising together project: Design and recruitment for a randomized, controlled trial to determine the benefits of partnered strength training for couples coping with prostate cancer. *Contemp Clin Trials*. 2012 Mar; 33(2): 342-50. (PMCID: PMC3268842)
- 110) Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer*. 2012 Mar; 10(1): 6-14.
- 111) Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Huang W, Rooney WD, Beer TM, Garzotto MG, Springer CS Jr. Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection. *Magn Reson Med*. 2012 Mar: Epub ahead of print.
- 112) Beer TM. Editorial comment on "A double blind randomized crossover study of oral thalidomide versus placebo in patients with androgen dependent prostate cancer treated by intermittent androgen ablation". (submitted)
- 113) Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen C, Higano CS, Beer TM, Hung DT, Scher HI, Jung M, Sawyers CL. Treatment of advanced prostate cancer with an antiandrogen that alters androgen receptor localization and DNA binding. (submitted)
- 114) Roalf DR, Berlow YA, Lebow MR, Salat DH, Beer TM, Janowsky JS. Androgen deprivation results in white matter loss as shown by diffusion tensor imaging. (submitted)
- 115) Graff JN, Beer TM. Editorial comment on "The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy". (submitted)
- 116) Agarwal N, Bellmunt J, Maughan B, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko Y, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-month progression-free survival as an endpoint to evaluate second-line therapy for advanced urothelial carcinoma. (submitted)
- 117) Garzotto M, Mongoue-Tchokote S, Collins L, Priest R, Spurgeon S, Peters LM, Beer TM, Mori M. Nomogram For The Prediction Of Gleason ≥ 7 Prostate Cancer in Men With a PSA of ≤ 10 ng/ml. (in preparation)
- 118) Luk BV, Nail LM, Perrin NA, Beer TM, Tolle SW, Lasarev M, Hall K, Kenworthy-Heinige T, Fromme EK. Do printed symptom reports influence clinical management? A longitudinal controlled trial of patient-reported outcomes in patients receiving chemotherapy. (in preparation)

Abstracts

- 1) Mawe GM, Beer TM, and Gershon MD. Cytochrome Oxidase Histochemistry: a Tool for the Study of the Ontogeny of Enteric Neuronal Activity. FASEB Summer Conference, Saxton River, Vermont; 1985.
- 2) Beer TM and Henner WD. Pulse Dosing Allows Substantial Dose Escalation of Calcitriol: a Phase I Clinical Trial in Advanced Malignancies. *Proceedings of the AACR* 40: 84, 1999.
- 3) A Einstein Jr, R Lush, R Rago, Y-j Ko, G Bublely, WD Henner, T Beer, G Chatta, R

- Shepard, P Unger, EA Merica, E Ette, MW Harding, and WS Dalton. A Phase II Study of Safety, Pharmacokinetics and Efficacy in Incel (biricodar, VX-710) in Combination with Mitoxantrone (M) and Prednisone (P) in Hormone Refractory Prostate Cancer (HRPC). Abstract #531, Proceedings of the 1999 AACR · NCI · EORTC International Conference, Clinical Cancer Research, Vol. 5 (Supplement), 1999.
- 4) Einstein A Jr, Lush R, Rago R, Ko Y-j, Bublely G , Henner WD, Beer TM, Chatta G, Shepard R, Unger P, Merica EA, Ette E, Harding MW, and Dalton WS. A Phase II Study of Safety, Pharmacokinetics and Efficacy in Incel (Biricodar, VX-710) in Combination with Mitoxantrone (M) and Prednisone (P) in Hormone Refractory Prostate Cancer (HRPC). CaPCure Annual Scientific Retreat, October 1999, Lake Tahoe, NV.
 - 5) Beer TM, Evans AJ, Lowe BA, and Henner WD. Glutathione S-Transferase Pi Polymorphism hGSTP*B and the Risk of Prostate Cancer. Proceedings of the AACR 41: 359, 2000.
 - 6) Henner WD, Evans AJ, Hough KM, Beer TM, and Lowe BA. The Pro/Pro genotype at position 72 in p53 is protective against the development of adenocarcinoma of the prostate. Proceedings of the AACR 41: 596, 2000.
 - 7) TM Beer, WC Pierce, BA Lowe, and WD Henner. Phase II Study of Weekly Docetaxel (Taxotere[®]) in Hormone Refractory Metastatic Prostate Cancer (HRPC). Proc Am Soc Clin Onc 19:348a, 2000.
 - 8) RP Rago, AB Einstein Jr, RM Lush III, Y Ko, TM Beer, G Chatta, RC Shepard, P Unger, EA Merica, E Ette, MW Harding, and WS Dalton. A Phase II Study of Safety, Pharmacokinetics and Efficacy in Incel (Biricodar, VX-710) in Combination with Mitoxantrone (M) and Prednisone (P) in Hormone Refractory Prostate Cancer (HRPC). Proc Am Soc Clin Onc 19: 180a, 2000.
 - 9) TM Beer, KM Hough, M Garzotto, WC Pierce, BA Lowe, and WD Henner. Treatment of Androgen-Independent Prostate Cancer with Weekly High-Dose Calcitriol and Docetaxel. Proc Am Soc Clin Onc 20: abstract 2369, 2001.
 - 10) Wagner M, Weksler N, Loos J, Beer TM, Barry JM, Garzotto M. Cox-2 expression and effects of selective inhibition in prostate cancer cell lines. Annual Northwest Urological Society Meeting. December 8, 2001.
 - 11) Wagner M, Weksler N, Loos J, Beer TM, Barry JM, Garzotto M. Cox-2 expression and effects of selective inhibition in prostate cancer cell lines. American Urological Assn Meeting, Abstract #542, 167:135, 2002.
 - 12) Beer TM, Garzotto M, O'Hara MF, Lowe BA, Montalto MA, Corless CL, and Henner WD. Randomized study of high-dose pulse calcitriol or placebo prior to prostatectomy. Proc Am Assoc Cancer Res 43:388, 2002.
 - 13) Evans AJ, Henner WD, Eilers KM, Montalto MA, Andersen PE, Cohen JI, Everts EC, McWilliams JE, and Beer TM. Polymorphisms of GSTT1 and Related Genes in Head and Neck Cancer Risk. Proc Am Assoc Cancer Res 43:406, 2002.
 - 14) Beer TM, Hough KM, Garzotto M, Lowe BA, and Henner WD. Androgen-independent prostate cancer (AIPC) treatment with weekly high-dose calcitriol and docetaxel. Proc Am Soc Clin Onc 21:177a, 2002.
 - 15) Lowe BA, Henner WD, Lemmon D, Urankar R, and Beer TM. Long term administration of high dose weekly oral calcitriol in patients with a rising PSA after definitive treatment for prostate cancer (PC): a phase II study. Proc Am Soc Clin Onc 21:158b, 2002.
 - 16) Garzotto M, Beer TM, Lowe BA, Ellis WJ, Lange PA, Montalto MA, and Higano CS. Neoadjuvant weekly docetaxel and mitoxantrone in patients with high risk localized prostate cancer: a phase I trial. Proc Am Soc Clin Onc 21:155b, 2002.
 - 17) Beer TM, Eilers KM, Garzotto M, Lowe BA, and Henner WD. Calcitriol and Docetaxel Treatment for Metastatic Androgen-Independent Prostate Cancer, Cancer Investigation 21 (Suppl. 1):61-62, 2002.

- 18) Beer TM, El-Geneidi M, Panagiotou I, Peters L, Hsieh Y-C, Mori M, and Garzotto M. Delayed curative therapy in patients who initially choose watchful waiting in the PSA era. *J Urol* 169(4 Suppl):492, 2003 (Abstract 1844)
- 19) Beer TM, Garzotto M, Lowe BA, Ellis WJ, Lange PA, Montalto MA, and Higano CS. Weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer. *J Urol* 169(4 Suppl):444, 2003 (abstract 1662)
- 20) Garzotto M, Panagiotou I, Hsieh Y-C, Mori M, Peters L, Klein T and Beer TM. Predictors of Delayed Prostate Cancer-Directed Intervention in Watchful Waiting Patients in the PSA Era. *J Urol* 169(4 Suppl):460, 2003 (abstract 1724)
- 21) Myrthue A, Hsieh Y-C, Mori M, O'Hara MF, Chin R, Yates J, Garzotto M, and Beer TM. DNA Microarray: pooling of RNA versus pooling of gene expression data in the analysis of human prostate cancer specimens. *Proc Am Assoc Cancer Res* 44:804, 2003.
- 22) Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, Beer TM. A Comparison of CT scan to Transrectal Ultrasound-Measured Prostate Volume in Untreated Prostate Cancer. *American Radium Society* 2003
- 23) Beer TM, Javle M, Whitehouse MJ, and Trump DL. Phase I Study and Pharmacokinetic (PK) Evaluation Of DN-101, a New Formulation of Calcitriol. *Proc Am Soc Clin Onc* 22:231, 2003.
- 24) Berry W and Beer TM. Efficacy and toxicity of weekly docetaxel in the elderly, a pooled comparison of outcome in men with androgen independent prostate cancer (AIPC) ≥ 70 vs < 70 years of age. *Proc Am Soc Clin Onc* 22:745, 2003.
- 25) Tiffany NM, Wersinger EM, Garzotto M, and Beer TM. Androgen-independent prostate cancer (AIPC) treatment with zoledronic acid and imatinib mesylate (STI-571). *Proc Am Soc Clin Onc* 22:421, 2003.
- 26) Wersinger EM, Garzotto M, Henner WD, Eilers KM, and Beer TM. Intermittent Chemotherapy in Metastatic Androgen-Independent Prostate Cancer. *Proc Am Soc Clin Onc* 22:394, 2003.
- 27) Eilers KM, Garzotto M, Henner WD, and Beer TM. Palliative activity of weekly high-dose calcitriol and docetaxel in androgen-independent prostate cancer (AIPC). *Proc Am Soc Clin Onc* 22:412, 2003.
- 28) Garzotto M, Beer TM, Peters L, Klein T, Hsieh Y-C, and Mori M. Improved Detection of Prostate Cancer using Classification and Regression Tree (CART) Analyses. *Proc Am Soc Clin Onc* 22:398, 2003.
- 29) Beer TM, Eilers KM, Garzotto M, Lowe BA, and Henner WD. Androgen-Independent Prostate Cancer (AIPC) Treatment with Weekly High-Dose Calcitriol (C) and Docetaxel (D). *North Central Section of the AUA*, 2003.
- 30) Myrthue A, Hsieh Y-C, Mori M, O'Hara MF, Chin R, Yates J, Garzotto M, and Beer TM. DNA Microarray: Pooling of RNA Versus Pooling of Gene Expression Data in the Analysis of Human Prostate Cancer Specimens. *Western Section of the AUA*, 2003
- 31) Bland LB, Tangen C, Crawford ED, and Beer TM. Anemia Is An Independent Adverse Prognostic Factor in Untreated Metastatic Prostate Cancer: An Analysis of SWOG 8894. *Western Section of the AUA*, 2003.
- 32) Garzotto M, Lowe BA, Ellis WJ, Lange PA, Montalto MA, and Higano CS, and Beer TM. Neoadjuvant Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients with High-Risk Localized Prostate Cancer. *Western Section of the AUA*, 2003.
- 33) Beer TM, Javle M, Henner WD, and Trump DL. Pharmacokinetics (PK) and Tolerability of DN-101, a new formulation of calcitriol, in patients with cancer. *AACR* 2004.
- 34) Beer TM, Bland LB, Garzotto M, Ryan CW, Janowsky JS. Effect of High Dose Estrogen May Enhance Memory in Men with Prostate Cancer. *Proc Am Soc Clin Onc* 23:417, 2004.
- 35) Purnell JQ, Bland LB, Garzotto M, Lemmon D, Ryan CW, Beer TM. Transdermal

- Estrogen Therapy Improves Cholesterol Levels and Lipid Profiles in Men with Prostate Cancer. *Proc Am Soc Clin Onc* 23:734, 2004.
- 36) Bland LB, Tangen CM, Thompson IM, Crawford ED, Beer TM. Prognostic Value of Anemia in Untreated Metastatic Prostate Cancer: A Multivariate Analysis of SWOG 8894. *Proc Am Soc Clin Onc* 23:399, 2004.
 - 37) Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM. How Good is Physician Reporting of Chemotherapy Adverse Effects? A Comparison to Patient-Reported Symptoms From the QLQ-C30. *Proc Am Soc Clin Onc* 23:730, 2004.
 - 38) Garzotto M, Mongoue-Tchokote S, Bledsoe J, Parra RO, Peters L, Park Y, Beer TM, Mori M. Predictors of Prostate Cancer in men Undergoing Serial Prostate Biopsies: Results from 371 Patients. *Proc Am Soc Clin Onc* 23:402, 2004.
 - 39) Janoff D, Mongoue-Tchokote S, Peterson C, Parra RO, Peters L, Park Y, Beer TM, Mori M, Garzotto M. Outcomes of Androgen Deprivation as Sole Therapy for Localized Prostate Cancer. *Proc Am Soc Clin Onc* 23:412, 2004.
 - 40) Brouns M, Beer TM, Ganzini L. Interest In Physician-Assisted Suicide (PAS) Among Oregon Cancer Patients. *Proc Am Soc Clin Onc* 23:743, 2004.
 - 41) Spurgeon S, Riavadeneira A, Peters LM, Hsieh Y-C, Beer TM, Mori M, Garzotto M. Prediction of Aggressive Prostate Cancer on Biopsy Using Classification and Regression Tree Analysis (CART). *Proc Am Soc Clin Onc* 23:435, 2004.
 - 42) Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High-Dose Calcitriol, Docetaxel, and Estramustine in Androgen-Independent Prostate Cancer (AIPC): A Phase I/II Study. *Proc Am Soc Clin Onc* 23:424, 2004.
 - 43) Higano CS, Beer TM, Garzotto M, Ryan CW, Pitzel M, Works CR, Hall SP. Need for Awareness and Monitoring of Ocular Toxicities (OT) Due to weekly Docetaxel Administration: Experience During a Trial of Neoadjuvant Docetaxel (D) and Mitoxantrone (M) for Patients with High-Risk Prostate Cancer (PC). *Proc Am Soc Clin Onc* 23:399, 2004.
 - 44) Rosenbaum E, Kibel A, Roth BJ, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaola RS, Beer TM, Eisenberger MA. Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy: Preliminary data of a multicenter pilot trial. *Proc Am Soc Clin Onc* 23:417, 2004.
 - 45) Nelson PS, Huang A, True LD, Garzotto M, Wersinger EM, O'Brien CA, Ryan CW, Ellis WJ, Lange PH, Higano CS, Beer TM. Molecular Correlates of Prostate Cancer Response and Resistance to Neoadjuvant Mitoxantrone and Docetaxel. *InterProstate SPORE Meeting*, Jan: 26, 2005.
 - 46) Sweeney C, Dobrolecki L, Beer T, Battiato L, Vinson J, Hickey R. Serum proteomic profiling can distinguish androgen sensitive prostate cancer patients from those with androgen resistant disease. *Proc Prost Ca Symp* 1:135, 2005
 - 47) Garzotto M, Collins L, Park Y, Mongoue-Tchokote S, Bledsoe J, Peters L, Blank BH, Beer TM, Mori M. PSA doubling time for the prediction of aggressive prostate cancer on repeat biopsy. *Proc Multidisciplinary Prostate Cancer Symposium* 1:64, 2005
 - 48) Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Early association between duration of androgen deprivation, life-style factors and bone mineral density in patients with prostate cancer: An analysis during the first 12 months of therapy. *Proc Prost Ca Symp* 1:108, 2005
 - 49) Beer TM, Hayes M, Donovan D, Emmons S, Katovic NM, Benavides M, Ryan CW, Liu G. Acupuncture for hot flashes in prostate cancer patients. *Proc Prost Ca Symp* 1:111, 2005
 - 50) Beer TM, Garzotto M, Lowe BA, Ryan CW, Rarick MU, Ellis WJ, Lange PH, Takayama T, Wersinger EM, Higano CS. Weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer: Results form 54 patients. *Proc Prost*

- Ca Symp 1:118, 2005
- 51) Montgomery B, Lin D, Ryan C, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel; a phase II study in patients with metastatic, androgen independent prostate cancer. Proc Prost Ca Symp 1:176, 2005
 - 52) Beer TM, Bland LB, Garzotto M, Purnell JQ, Ryan CW, Deloughery TG, Wersinger EM, Lemmon D. Transdermal estradiol in androgen-independent prostate cancer (AIPC). Proc Prost Ca Symp 1:181, 2005
 - 53) Kibel AS, Picus J, Cookson MS, Roth B, Jarrard DF, Wilding G, Klein EA, Dreicer R, Nelson JB, Chatta G, Benson MC, Petrylack DP, DiPaola R, Beer TM, Diamond J, Partin AW, Eisenberger MA. Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy. J Urol 173(4):222, 2005
 - 54) Ryan CW, Dezheng H, Stallings JW, Davis RL, Beer TM, McWhorter LT. Early association between duration of androgen deprivation, life-style factors and bone mineral density in patients with prostate cancer: an analysis during the first 12 months of therapy. J Urol 173(4):222, 2005
 - 55) Garzotto M, Collins L, Priest R, Spurgeon S, Hsieh YC, Beer TM, Mori M. Nomogram for the prediction of high-grade prostate cancer on ultrasound-guided needle biopsy. Proc Am Soc Clin Onc 23 (16S):408s, 2005
 - 56) Spurgeon S, Garzotto M, Collins L, Priest R, Hsieh YC, Peters L, Beer TM, Mori M. Utility of PSA doubling time (PSADT) in the detection of prostate cancer in men with a serum PSA < 10 ng/ml. Proc Am Soc Clin Onc 23 (16S):408s, 2005
 - 57) Montgomery B, Lin D, Ryan C, Garzotto M, Beer T. Diethylstilbestrol and docetaxel: a phase II study in patients with metastatic, androgen independent prostate cancer. Proc Am Soc Clin Onc 23 (16S):408s, 2005
 - 58) O'Brien CA, Garzotto M, Higano CS, Wersinger EM, Kaimaktchiev V, Corles CL, Lange PH, Ryan CW, True LD, Beer TM. Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel. Proc Am Soc Clin Onc 23 (16S):408s, 2005
 - 59) Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaula RS, Beer TM, Eisenberger M. A pilot multicenter phase II study of adjuvant docetaxel for high risk prostate cancer patients after radical prostatectomy: preliminary data. Proc Am Soc Clin Onc 23 (16S):408s, 2005
 - 60) Hayes M, Katovic NM, Donovan D, Emmons S, Benavides M, Montalto M, Ryan CW, Liu G, Beer TM. Acupuncture for hot flashes in prostate cancer patients. Proc Am Soc Clin Onc 23 (16S):408s, 2005
 - 61) Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether JD, Henner WD, Chi KN, Cruickshank S. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Onc 23 (16S):408s, 2005
 - 62) Beer TM, Ryan CW, Venner P, Petrylak D, Chatta G, Ruether J, Chi K, Arroyo A, Clow F. ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Proc Euro Cancer Conf 2005.
 - 63) Beer TM, Higano CS. Darbepoetin administered every 4 weeks for anemia in advanced prostate cancer patients. Proc Prost Ca Symp 2006.
 - 64) Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid (ZA) initiated during the first year of androgen deprivation therapy (ADT) increases bone mineral density (BMD) and suppresses bone turnover markers in prostate cancer patients. Proc Prost Ca Symp 2006.
 - 65) Beer TM, Ryan CW, Venner P, Petrylak DP, Chatta G, Ruether JD, Chi KN. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results

- from ASCENT. Proc Prost Ca Symp 2006.
- 66) Chan JS, Beer TM, Quinn DI, Garzotto M, Sokoloff M, Ryan CW. Phase II study of DN-101 (high dose calcitriol), mitoxantrone, and prednisone in androgen-independent prostate cancer (AIPC). Proc Prost Ca Symp 2006.
 - 67) Venner PM, Ryan CW, Petrylak DP, Chatta G, Ruether JD, Chi KN, Curd J, Beer TM. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. Proc Prost Ca Symp 2006.
 - 68) Montgomery B, Lin DW, Ryan CW, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: A phase II study in patients with metastatic, androgen-independent prostate cancer. Proc Prost Ca Symp 2006.
 - 69) Graff J, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Predictors of overall (OS) and cancer-specific survival (CSS) in patients with clinically localized prostate cancer treated with primary androgen deprivation therapy: Results from PCOS. Proc Prost Ca Symp 2006.
 - 70) O'Brien CA, True LD, Higano CS, Garzotto M, Takayama T, Ellis WJ, Lange PH, Katovic NM, Ryan CW, Beer TM. Histologic patterns in radical prostatectomy (RP) specimens of high-risk prostate cancer patients treated with neoadjuvant chemotherapy are predictive of nodal metastases. Proc Prost Ca Symp 2006
 - 71) Venner PM, Ryan C, Petrylak DP, Chatta GS, Ruether J, Chi KN, Curd J, Beer TM. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. Proc Am Soc Clin Onc 24 (18S): 218s, 2006
 - 72) Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether J, Chi KN, Arroyo A, Clow FW. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT. Proc Am Soc Clin Onc 24 (18S): 221s, 2006
 - 73) Ryan CW, Goldman BH, Lara PN, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon- α 2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc Am Soc Clin Onc 24 (18S): 223s, 2006
 - 74) Graff J, Mori M, Li H, Garzotto M, Penson D, Potosky A, Beer TM. Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study. Proc Am Soc Clin Onc 24 (18S): 244s, 2006
 - 75) Chan JS, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether J, Chi KN, Young J, Shen C, Beer TM. Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. Proc Am Soc Clin Onc 24 (18S): 245s, 2006
 - 76) Garzotto M, Mongoue-Tchokote S, Shannon J, Peters L, Sokoloff MH, Beer TM. Effect of obesity on PSA density (PSAD): A new clinical predictor of prostate cancer. Proc Am Soc Clin Onc 24 (18S): 245s, 2006
 - 77) Montgomery B, Lin D, Ryan C, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: A phase II study in patients with metastatic androgen independent prostate cancer. Proc Am Soc Clin Onc 24 (18S): 248s, 2006
 - 78) O'Brien CA, Mongoue-Tchokote S, Collins L, Spurgeon S, Peters L, Beer TM, Mori M, Garzotto M. Assessment of PSA and digital rectal examination (DRE) for the detection of Gleason ≥ 7 prostate cancer in a referral population. Proc Am Soc Clin Onc 24 (18S): 249s, 2006
 - 79) Oh WK, Manola J, Ross RW, Berkowitz A, Ryan CW, Eilers KM, Beer TM. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results. 639s Proc Am Soc Clin Onc 24 (18S): 639s, 2006

- 80) Beer TM, Lalani AS, Lee S, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner PM, Ruether JD, Chi KN. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial. Proc Prost Ca Symp: 181, 2007
- 81) Oh WK, Jacobus S, Ross R, Inman M, Taplin M, Ryan C, Eilers K, Beer T. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. Proc Prost Ca Symp: 190, 2007
- 82) Rogosin S, Mongoue-Tchkote S, Beer TM, Mori M, Collins L, Garzotto M. PSA density as a predictor of aggressive prostate cancer on repeat prostate biopsy. Proc Prost Ca Symp: 74, 2007
- 83) Rosenberg JE, Weinberg VK, Beer T, Beekman KW, Mathew P, Hutcheon D, Small EJ. NCI 7347: Phase I/II trial of epothilone analog BMS-247550 (ixabepilone), mitoxantrone, and prednisone in hormone refractory prostate cancer patients previously treated with chemotherapy. Proc Prost Ca Symp: 204, 2007
- 84) Scher HI, Halabi S, Tannock I, Morris M, Higano C, Beer T, Sternberg C, Eisenberger M, Martin A, Maha H. The prostate cancer clinical trials working group (PCCTWG) consensus for phase II trials in metastatic castration-resistant prostate cancer. Proc Prost Ca Symp: 182, 2007
- 85) Zurita AJ, Shore N, Kozloff M, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis C. Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHRPC). Proc Prost Ca Symp: 186, 2007
- 86) Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Chow Maneval E, Chen I, Logothetis CJ. A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC). Proc ECCO 14 Conf: 1043, 2007
- 87) Rogosin S, Collins L, Mongoue-Tchokote S, Blank BH, Beer TM, Mori M, Garzotto M. PSA density as a predictor of aggressive prostate cancer on repeat prostate biopsy. Proc Am Soc Clin Onc: 25 (18S): 236s, 2007
- 88) Beer TM, Bernstein GT, Corman JM, Glode ML, Hall S, Poll WL, Schellhammer PF, Xu Y, Yu L, Frohlich MW. Randomized trail of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). Proc Am Soc Clin Onc: 25 (18S): 249s, 2007
- 89) Graff J, Lalani AS, Lee S, Curd JG, Henner WD, Ryan CW, Venner PM, Ruether JD, Chi KN, Beer TM. C-reactive protein as a prognostic marker for men with androgen-independent Fprostate cancer (AIPC): Results from the ASCENT trial. Proc Am Soc Clin Onc: 25 (18S): 253s, 2007
- 90) Goldman BH, Lara Jr PN, Beer TM, Mack PC, Drabkin HA, Holland WS, Crawford E, Ryan CW. Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): An analysis of SWOG 0412. Proc Am Soc Clin Onc: 25 (18S): 261s, 2007
- 91) Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis CJ. Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa). Proc Am Soc Clin Onc: 25 (18S): 268s, 2007
- 92) Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM, Perrin N. Prognostic significance of patient-physician disagreement about performance status in patients with advanced cancer. Proc Am Soc Clin Onc: 25 (18S): 498s, 2007
- 93) Lopez CD, Beer T, Todd K, Blanke CD. A phase II trial of high-dose calcitriol and docetaxel in patients with untreated, incurable pancreatic adenocarcinoma. Proc Am Soc

- Clin Onc: 25 (18S): 641s, 2007
- 94) Garzotto M, Janeba N, Eilers KM, Sekhon H, Beer TM. Pre-prostatectomy study of the effect of celecoxib versus placebo on androgen receptor (AR) expression in prostate cancer. Proc Am Soc Clin Onc: 25 (18S): 652s, 2007
 - 95) Chan JS, Vuky J, Besaw LA, Beer TM, Ryan CW. A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC). Proc Am Soc Clin Onc: 25 (18S): 657s, 2007
 - 96) Weinberg VK, Beekman K, Hutcheon D, Beer T, Rosenberg JE, Small EJ. NCI 7347: Phase 1/2 Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer Patients Previously Treated with Chemotherapy: Results of a DOD Prostate Cancer Therapy Consortium Trial. Proc IMPaCT: 70(S36-1), Sept 2007
 - 97) Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Maneval EC, Chen I, Logothetis CJ, Beer TM. Phase 1 Study of Sunitinib in Combination with Docetaxel and Prednisone in Metastatic Castrate-resistant Prostate Cancer (CRPC). Proc IMPaCT: 71(S36-4), Sept 2007
 - 98) Krause MA, Beer TM, Janowsky JS. The Brain Basis of Memory Loss with Androgen Deprivation Therapy: Methods Development and Preliminary Findings. Proc IMPaCT: 101(P2-10), Sept 2007
 - 99) Higano C, Lange PH, True L, Beer TM, Garzotto M, Huang CY, Nelson PS, Vessella R. Targeting Mechanisms of Resistance to Taxane-based Chemotherapy. Proc IMPaCT: 174(P13-2), Sept 2007
 - 100) Harzstark AL, Weinberg VK, Sharib J, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Ryan CJ, Small EJ, Rosenberg JE. Second-line combination chemotherapy: A phase I trial of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC) previously treated with chemotherapy. Proc GU Ca Symp: 178, Feb 2008
 - 101) Ryan CW, Curti BD, Pattee KJ, Besaw L, Beer TM, Fisher B. A dose-escalation phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). Proc GU Ca Symp: 273, Feb 2008
 - 102) Farha GN, Taioli E, Cauley JA, Zmuda JM, Orwoll E, Bauer DC, Wilt TJ, Hoffman AR, Beer TM, Shikany JM, Daniels N, Chan J, Fink HA, Barrett-Connor E, Parsons JK, Bunker CH. The Association of Bone Mineral Density with Prostate Cancer Risk: the Osteoporotic Fractures in Men (MrOS) Study. Proc AACR: 3849, Apr 2008
 - 103) Scher HI, Beer T, Higano CS, Danila DC, Shelkey J, Hirmand M, Hung D, Morris MJ, Larson SM, Sawyers CL. Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer. Proc AACR: LB-203, Apr 2008
 - 104) Beer TM, Slovin SF, Higano CS, Tejwani S, Dorff TB, Stankevich E, Lowy I. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). Proc Am Soc Clin Onc: 26(15S): 251s, Jun 2008
 - 105) Scher HI, Beer TM, Higano CS, Danila DC, Montgomery B, Shelkey J, Hirmand M, Hung D, Sawyers C. Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Onc: 26(15S): 251s, Jun 2008
 - 106) Taplin M, Ko Y, Regan MM, Beer TM, Carducci MA, Mathew P, Bublely G, Oh WK, Kantoff PW, Balk SP. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). Proc Am Soc Clin Onc: 26(15S): 266s, Jun 2008
 - 107) Graff J, Smith DC, Neerukonda L, Alonso M, Jones GR, Beer TM. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with

- metastatic androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Onc: 26(15S): 284s, Jun 2008
- 108) Harzstark AL, Weinberg VK, Sharib J, Smith DC, Hussain MH, Beer TM, Ryan CW, Mathew P, Ryan CJ, Small EJ, Rosenberg JE. Second-line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC) refractory to docetaxel-based therapy. Proc Am Soc Clin Onc: 26(15S): 287s, Jun 2008
- 109) Fromme E, Nail L, Tolle S, Perrin N, Kenworthy-Heinige T, Beer TM. Using tablet computers to collect clinical and research data: Ease-of-use analysis. Proc Am Soc Clin Onc: 26(15S): 732s, Jun 2008
- 110) Beer TM, Smith DC, Hussain A, Alonso M, Neerukonda L, Hauke R, Giurescu M, Wang Y. Phase II study of first-line sagopilone combined with prednisone in patients with metastatic androgen-independent prostate cancer. Proc Euro Soc Med Onc: 438, Sept 2008
- 111) Scher H, Beer T, Higano C, Logothetis C, Shelkey J, Hung D, Hirmand M, Larson S, Fleisher M, Sawyers C. Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials Consortium. Proc EORTC-NCI-AACR Symp: 160, 2008
- 112) Scher HI, Beer TM, Higano CS, Logothetis C, Anand A, Hirmand M, Hung D, Larson S, Fleisher M, Sawyers C. Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC). Proc 2009 GU Ca Symp: 151, Feb 2009
- 113) Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Smith DC, Mathew P, Beer TM, Liu G, Small EJ. A phase II study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPC) refractory to docetaxel-based therapy. Proc 2009 GU Ca Symp: 160, Feb 2009
- 114) Basch EM, Burke L, Kane R, Carducci M, Beer TM, George D, Fruscione M, Sit L, Morris M, Scher HI. Prevalence and severity of pain in men with metastatic prostate cancer. Proc 2009 GU Ca Symp: 205, Feb 2009
- 115) Li X, Priest RA, Siddiqui F, Beer TM, Garzotto MG, Woodward WJ, Rooney WD, Springer CS. Systematic DCE-MRI Parameter Errors Caused by Disproportionate Transverse Relaxation (T2*) Quenching of Tissue Compartmental Water Proton Signals. Proc ISMRM 2009 An Mtg: 6836, Apr 2009
- 116) Graff JN, Rademacher BLS, Qian DZ, Beer TM. C-reactive protein-induced docetaxel resistance in prostate cancer. Proc 100th Ann Mtg AACR: Abstr 3876, Apr 2009
- 117) Wu M, Huang CY, Sim HG, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS. Chemotherapy-induced monoamine oxidase A expression in prostate carcinoma associates with clinical outcome and functions as a cytoprotective resistance enzyme through HIF1 pathway. Proc 100th Ann Mtg AACR: Abstr 5524, Apr 2009
- 118) Scher HI, Beer T, Higano C, Efsthathiou E, Anand A, Hirmand M, Hung D, Larson S, Fleisher M, Sawyers C. Clinical study of MDV3100 in progressive castration-resistant prostate cancer (CRPC). Proc 2009 AUA Ann Mtg: 181: 230: Abstr 641, Apr 2009
- 119) Scher HI, Beer TM, Higano CS, Taplin M, Efsthathiou E, Anand A, Hung D, Hirmand M, Fleisher M. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5011, May 2009
- 120) Small E, Harzstark A, Weinberg VK, Smith DC, Mathew P, Beer T, Liu G, Sharib J, Rosenberg J. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5058, May 2009
- 121) Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, Wang Y. Phase II study

- of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC). Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5059, May 2009
- 122) Rademacher BL, Garzotto M, Higano CS, O'Brien CA, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM. Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5121, May 2009
 - 123) Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M, Callahan JA, Gordon G, Reich S, Carducci MA. A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naïve prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5135, May 2009
 - 124) Slovin SF, Beer TM, Higano CS, Tejwani S, Hamid O, Picus J, Harzstark A, Scher HI, Lan Z, Lowy I. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5138, May 2009
 - 125) Higano C, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K, Katz T, Yousoufian H, Schwartz J. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer (CRPC). Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5142, May 2009
 - 126) Prins R, Rademacher BL, Mongoue-Tchokote S, Eilers KM, Beer TM. C-reactive protein as adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5168, May 2009
 - 127) Vinson J, Mathew P, Beer TM, Carducci MA, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher HI. Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr e16065, May 2009
 - 128) Ryan CW, Vuky J, Chan JS, Beer TM, Rothkopf M. Phase II study of everolimus (E) with imatinib (IM) in patients with previously-treated renal carcinoma (RCC). Proc 2009 ASCO Ann Mtg: 27(15S): Abstr e16075, May 2009
 - 129) Hayes M, Reeder C, Beer TM. Acupuncture for hot flashes for prostate cancer patients. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr e16125, May 2009
 - 130) Basch EM, Sit L, Fruscione M, Burke L, Kane R, George D, Carducci MA, Matthew P, Beer TM, Scher HI. Pain and analgesic use in men with metastatic prostate cancer. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr e20515, May 2009
 - 131) Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro L, Beer T, Liu G, Mathew P, Lin AM, Fong L, Small EJ. Ixabepilone, Mitoxantrone, and Prednisone for Metastatic Castrate Resistant Prostate Cancer (CRPC) After Docetaxel-Based Therapy - A Phase 2 Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Proc 16th Ann PCF Sci Retreat: Abstr 34, Sept 2009
 - 132) Scher H, Beer T, Higano C, Danila D, Montgomery B, Shelkey J, Hirmand M, Hung D, Anand A, Fleisher M, Sawyers C. Antitumor activity of MDV3100 in a phase 1-2 trial in castration resistant prostate cancer conducted by the Prostate Cancer Clinical Trials Consortium. Proc 16th Ann PCF Sci Retreat: Abstr 92, Sept 2009
 - 133) Vinson J, Morris M, Beer T, Carducci M, Corn P, DiPaola R, George D, Heath E, Higano C, Hussain M, Kantoff P, Small E, Stadler W, Wilding G, Slovin S, Rathkopf D, Warren M, Scher HI. The Prostate Cancer Clinical Trials Consortium (PCCTC): A collaborative multicenter prostate cancer research model. Proc 16th Ann PCF Sci Retreat: Abstr 93, Sept 2009
 - 134) Young LA, Lebow MR, Roalf DR, Beer TM, Janowsky JS. Prefrontal activity does not reflect androgen deprivation induced memory impairment. Proc Neuroscience 2009, Oct

- 2009 (submitted)
- 135) Small EJ, Beer TM, Weinberg VK, Higano CS, Alumkal JJ, Yu EY, Nordquist LT, Rosenberg JE, Sun J, Lin AM. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the Department of Defense Prostate Cancer Clinical Trials Consortium. Proc 2010 GU Ca Symp: 74: Abstr 41, Mar 2010
 - 136) Scher HI, Anand A, Beer TM, Higano CS, Danila DC, Hirmand M, Larson SM, Sawyers CL, Fleisher M, Heller G. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100: Toward the development of a biomarker basket. Proc 2010 GU Ca Symp: 107: Abstr 173, Mar 2010
 - 137) Higano CS, Alumkal JJ, Ryan CJ, Yu EY, Beer TM, Fox FE, Dontabhaktuni A, Youssoufian H, Schwartz JD. A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): Feasibility of every 3-week dosing and updated results of every 2-week dosing. Proc 2010 GU Ca Symp: 111: Abstr 189, Mar 2010
 - 138) Scher HI, Beer TM, Higano CS, Logothetis C, Taplin ME, Efstathiou E, Hirmand M. Antitumor activity of MDV3100 in a phase 1-2 study of advanced prostate cancer. Proc 2010 Amer Urol Assoc Ann Mtg: 183(4):e227, Abstr 580, Apr 2010
 - 139) Tagge I, Priest RA, Beer TM, Garzotto MG, Woodward WJ, Huang W, Springer CS, Li X. Population-Generalized vs. Individual-Specific AIF in Human Prostate DCE-MRI Pharmacokinetic Analysis. Proc ISMRM-ESMRMB Joint Ann Mtg: 18: Abstr 2738, May 2010
 - 140) Priest RA, Li X, Tagge IJ, Woodward WJ, Beer TM, Springer CS, Garzotto MG. Multi-Slice Parametric Mapping in Prostate DCE-MRI. Proc ISMRM-ESMRMB Joint Ann Mtg: 18: Abstr 2809, May 2010
 - 141) Garzotto M, Hung A, Beer TM, Farris PE. Phase I/II study of preoperative intensity-modulated radiation therapy (IMRT) and docetaxel for high-risk prostate cancer: A platform for radiosensitizer development. Proc 2010 ASCO Ann Mtg: 28(15S): 43s; Abstr TPS250, May 2010
 - 142) Ryan CW, Curti BD, Quinn DI, Strother JM, Chen Z, Roberson E, Beer TM, Nauman D. A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). Proc 2010 ASCO Ann Mtg: 28(15S): 348s; Abstr 4528^, May 2010
 - 143) Anand A, Scher HI, Beer TM, Higano CS, Danila DC, Taplin M, Efstathiou E, Hirmand M, Sawyers CL, Heller G. Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. Proc 2010 ASCO Ann Mtg: 28(15S): 353s; Abstr 4546, May 2010
 - 144) Beer TM, Rademacher BL, Geng H, Pittsenbarger J, Garzotto M, Nelson P, Higano CS, Qian DZ. Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity. Proc 2010 ASCO Ann Mtg: 28(15S): 353s; Abstr 4548, May 2010
 - 145) Fleming MT, Kolodziej MA, Awasthi S, Hutson TE, Martincic D, Sonpavde G, Wang Y, Boehm KA, Asmar L, Beer TM. Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy. Proc 2010 ASCO Ann Mtg: 28(15S): 355s; Abstr 4555, May 2010
 - 146) Small EJ, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, Alumkal JJ, Yu EY, Sun J, Lin AM. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. Proc 2010 ASCO Ann Mtg: 28(15S): 387s;

- Abstr 4684, May 2010
- 147) Hirmand M, Scher HI, Beer T, Higano CS, Taplin M, Efstathiou E. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. Proc 35th ESMO Congress: 21(8): viii277, Abstr 884P, Oct 2010
- 148) Anand A, Scher HI, Danila DC, Beer TM, Higano CS, Taplin ME, Efstathiou E, Hirmand M, Sawyers CL, Heller G. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve (CN) patients (pts) with progressive castration resistant prostate cancer (CRPC) treated with MDV3100. Proc ASCO-NCI-EORTC Ann Mtg Mol Markers Ca: Abstr 39, Oct 2010
- 149) Harzstark AL, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, Alumkal JJ, Yu EY, Mi J, Small EJ. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. Proc 2011 GU Ca Symp: 29: 7s, Abstr 133, Feb 2011
- 150) Higano CS, Beer TM, Taplin M, Efstathiou E, Anand A, Hirmand M, Fleisher M, Scher HI. Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study. Proc 2011 GU Ca Symp: 29: 7s, Abstr 134, Feb 2011
- 151) Ferrari AC, Stein MN, Alumkal JJ, Gomez-Pinillos A, Catamero DD, Mayer TM, Collins F, Beer TM, DiPaola RS. A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy. Proc 2011 GU Ca Symp: 29: 7s, Abstr 156, Feb 2011
- 152) Beer T. MAOA inhibition during docetaxel therapy: A strategy to block tumor adaptation to docetaxel. Proc 2011 Innovative Minds Prost Ca Today (IMPACT) Conf: Abstr S8-1, Mar 2011

V. SERVICE

Membership in Professional Societies:

1992	American College of Physicians
1992	Oregon Medical Association
1992	Medical Society of Metropolitan Portland
1996	American Society of Clinical Oncology
1996	American Society of Hematology (Associate)
1998	American Association for Cancer Research
1999	Southwest Oncology Group
	Member GU Committee
	Principal Investigator – OHSU UCOP
2003	American Urological Association (Affiliate)
2008	Radiation Therapy Oncology Group (RTOG)
2012	Oregon Society of Medical Oncology (OSMO)

Granting Agency Review Work:

Grant reviewer for:

Cancer Research UK
 ASCO Young Investigator Grant
 National Cancer Institute of Canada
 National Science Foundation

Doris Duke Foundation Distinguished Clinical Scientist Grant, 2006
American Association for the Advancement of Science (AAAS), University of
Kansas Medical Center Research Institute's (KUMC RI) Clinical Pilot Research
Fund Grant Program, 2009

Study section member for:

Congressional Directed Medical Research Program (DoD), 2008

Editorial and Ad Hoc Review Activities:

Editorial Board Member:

2005 - Reviews on Recent Clinical Trials
2006 - Anti-Cancer Drugs
2006 - Clinical GU Cancer
2007 - Libertas Academica
2009 - HCPLive.com Oncology Advisory Board
2009 - Oncology & Biotech News
2009 - Contemporary Oncology
2010 - Clinical Medicine Insights: Urology
2010 - Clinical Genitourinary Cancer

Reviewer:

Anti-Cancer Drugs
British Journal of Cancer
Cancer Chemotherapy and Pharmacology
Clinical Cancer Research
Clinical Pharmacology and Therapeutics
Clinical Prostate Cancer
Drugs and Aging
Expert Opinion on Pharmacotherapy
European Journal of Clinical Nutrition
Journal of the American Medical Association
Journal of Clinical Oncology
Journal of the National Cancer Institute
Journal of Urology
Lancet Oncology
Molecular Cancer Therapeutics
Nature Clinical Practice Urology
Oncology (Karger)
Prostate Cancer and Prostatic Diseases
Urology

Advisory Board Member:

Oncology Net Guide
Michael J. Hennessy & Associates Oncology Publications
Contemporary Oncology

Committees:

International/National

2000 - GU Committee, Southwest Oncology Group
2003- 2007 Geriatric Oncology Consortium, Scientific Advisory Board
2004 - 2006 American Society of Clinical Oncology, Annual Meeting Program Committee
2006 - 2009 American Society of Clinical Oncology, Cancer Education Committee

2006 – 2007 American Urological Association, Annual Meeting Abstract Review Committee
2007 - National Inter-SPORE Immunotherapy Working Group
2008 - 2008 Congressionally Directed Medical Research Programs, Scientific Peer Review Panel
2010 Co-Chair, 2010 Inaugural NCI-PCF Metastatic Prostate Cancer Treatment Sciences Meeting
2010-2011 Prostate Cancer Foundation (PCF) Research Awards, Review Committee
2011 Genitourinary Track Leader, 2011 ASCO Annual Meeting Scientific Program Committee

Regional

2004 - Oregon Partnership for Cancer Control, State Cancer Plan Development Committee
2004 - 2010 American Cancer Society, Harvey Baker Memorial Committee

Institutional

2000 - Member, OCC Leadership Council
2000 - 2001 Co-Chair, Program Committee, 2001 OHSU Prostate Cancer Conference
2001 - 2002 Member, Search Committee for Director of the Advanced Imaging Research Center
2003 - 2005 Member, Search Committee for Associate Director of the OHSU Cancer Institute
2003 Chair, Program Committee, 2003 OHSU/UW/ACS Prostate Cancer Conference
2003 - Member, OCI Senior Leadership Council
2004 - 2005 Member, OCI Clinical Advisory Council
2004 - Member, OCI Executive Council
2005 Chair, Program Committee, 2005 OHSU/UW/ACS Prostate Cancer Conference
2005 - Medical Director, Oncology Service Line
2006 - 2009 Member, School of Medicine Promotion and Tenure Committee
2006 Member, Graduate Faculty of the School of Medicine of the OHSU
2006 - Member, Research Pharmacy Task Force
2006 - 2007 Member, Search Committee for Chief of Urology
2007 Member, OCTRI K13 Multidisciplinary Advisory Committee
2007 Chair, Program Committee, 2007 OHSU/UW Prostate Cancer Conference
2008 - 2009 Chair, Search Committee for Chief of Urology
2008 Member, Cancer Institute's RFA for Pilot Projects and Career Development Scientific Review Committee
2008 Member, Oncology Executive Advisory Board Committee
2008 Member, Advanced Imaging Research Center (AIRC) Institutional Advisory Board (IAD)
2009 Member, OCTRI Internal Advisory Board Committee
2009 Chair, Program Committee, 2009 OHSU/UW Prostate Cancer Conference

Departmental

1999 – 2000 Fellowship Committee, Division of Hematology and Medical Oncology

Community Service:

2001 - 2002 Section Medical Editor, *Understanding Advanced Prostate Cancer*, an interactive educational software program
2001 - Media Consultant, ABC News
2008 Reviewer, *Treating Prostate Cancer – A Guide for Men with Localized Prostate Cancer* (Pub. No.: 08-EHC010-2A, July 2008), Agency for Healthcare Research

- 2008 and Quality (AHRQ) consumer's guide
Reviewer, Treatments for Clinically Localized Prostate Cancer (Pub. No.: 08-EHC010-3, July 2008), Agency for Healthcare Research and Quality (AHRQ) clinician's guide
- 2009 Faculty Member, Expert Guidance in Defining and Treating Hormone-Refractory Prostate Cancer, a web-based educational tool

Clinical Responsibilities (since last promotion):

Clinical responsibilities include 1¾ days of clinic per week. The practice is fully focused on prostate cancer. In addition, clinical responsibilities include 1 month of attending on the inpatient oncology service and 1 month of attending on the oncology consult service (both OHSU and VA simultaneously)

VI. TEACHING (OHSU Educator's Portfolio):

Overview of your Role as an Educator:

Through my many teaching roles including (1) direct mentor in research, (2) clinical mentor in the outpatient practice, (3) lecturer to a broad range of audiences, (4) author of many educational publications, and (5) leader of educational programs, I reach a broad range of learners including: high school students, college students, medical students, residents, fellows, junior faculty, general practitioners, practicing oncologists, patients, and the general public.

Scholarship of Teaching:

Curriculum Development

Developed Curriculum for the Annual Prostate Cancer Conference in 2001, 2003, 2005, 2007, and 2009

Assisted in the development of the Division Oncology curriculum.

Oversee and approve curricula for many regional oncology conferences on behalf of the American Society of Clinical Oncology Cancer Education Committee

Coordinate and set the curricular expectations for the GU Oncology Tumor Board and Prostate Cancer Journal Club/Research conference, both of which meet weekly

Oversaw national annual meeting program for the ASCO annual meeting while a member of the program committee

Educational Publications

Peer-reviewed Review Articles

- 1) Beer TM and Raghavan D, Chemotherapy for Hormone-Refractory Prostate Cancer: Beauty is in the Eye of the Beholder. *The Prostate* 45(2):184-193, 2000.
- 2) Beer TM, El-Geneidi, and Eilers KM. Docetaxel in the Treatment of Prostate Cancer. *Expert Review of Anticancer Therapy*, 3(3):261-268, 2003.
- 3) Culkin D and Beer TM. Advanced Penile Carcinoma. *Journal of Urology*, 170(2):359-365, 2003.
- 4) Beer TM. Development of Weekly High-Dose Calcitriol Based Therapy For Prostate Cancer. *Urologic Oncology*, 21(5):399-405, 2003.
- 5) Beer TM and Myrthue A. Calcitriol in Cancer Treatment: From the Lab to the Clinic. *Molecular Cancer Therapeutics*, 3:373-381, 2004.
- 6) Beer TM and Bubalo JS. Prevention and management of prostate cancer chemotherapy complications. *Urologic Clinics of North America*, 31(2):367-78, 2004.
- 7) Strother J, Beer TM and Dreicer R. Novel Cytotoxic and Biological Agents for Prostate

- Cancer – Where will the Money be in 2005? *European Journal of Cancer*, 41:954-64, 2005.
- 8) Beer TM. ASCENT: AIPC Study of Calcitriol Enhancing Taxotere, *BJU International*, in press, 96:508-513, 2005.
 - 9) Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high risk localized prostate cancer. *Urol Oncol*, 24(3):254-9, 2006.
 - 10) Beer TM and Myrthue A. Calcitriol in the Treatment of Prostate Cancer. *Anticancer Research*, 25(4A):2647-2651, 2006.
 - 11) Lycette JL, Bland LB, Garzotto M, and Beer TM. The Case for Parenteral Estrogens for Prostate Cancer. *Clinical GU Cancer*, 5:198-205, 2006.
 - 12) Sternberg CS, Krainer M, Oh WK, Bracada S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, and Fitzpatrick JM. The medical management of prostate cancer: a multidisciplinary team approach, *BJU International*. 2007 Jan;99(1):22-7.
 - 13) Ryan CJ, Beer TM. Prostate specific antigen only androgen-independent prostate cancer: natural history, challenges in management, and clinical trial design, *J Urol*. 2007 Sept;178(3 Pt 2):S25-9.
 - 14) Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference, *J Urol*. 2007 Sept;178(3 Pt 2):S5-8.
 - 15) Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI. American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Non-hormonal Therapy for Men with Metastatic Hormone-refractory (Castration-resistant) Prostate Cancer, *J Clin Oncol*. 2007 Oct;25(33):5313-5318.
 - 16) Beer TM, Ryan CW. The hazards of intermediate endpoints, *Cancer*. 2007 Nov;110(9):1877-1879.
 - 17) Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. *Clin Genitourin Cancer*. 2009 Jan;7(1):51-7.
 - 18) Schnadig ID, Beer TM. Optimal timing of chemotherapy in androgen independent prostate cancer. *Urol Oncol*. 2009 Jan-Feb;27(1):97-100.

Non-peer-reviewed

Books

None

Chapters

- 1) Panagiotou I, Beer TM. "Salvage chemotherapy and emerging drugs in germ cell tumors." *American Cancer Society Atlas of Germ Cell Tumors*. Raghavan D ed. 2003. 182-98.
- 2) Beer TM, Myrthue A. "Vitamin D Analogs and Their Role in Prostate Cancer." *Prostate Cancer Translational and Emerging Therapies*. Dawson NA, Kelly WK ed. Informa Healthcare USA, Inc.: New York, 2007. 257-79.
- 3) Jensen AR, Szmulewitz RZ, Beer TM, Posadas EM. Calcitriol and Vitamin D Analogs, submitted.
- 4) Barnett CM, Beer TM. Vitamin D and Prostate Cancer, submitted.

Electronic Publications

- 1) Beer TM and Garzotto M. When you hear hoofbeats, don't forget zebras: SIADH associated with prostate cancer. Guest Editorial, *Urohealth*,

http://www.urohealth.org/editorials/display_editorial.asp?EDITORIAL_ID=157&EDITORIAL_CAT=PRO, 2002.

- 2) Beer TM. Prostate Cancer: Improving Screening, Treatment, and Prognosis. Medscape <http://www.medscape.com/viewarticle/436143>, 2002.
- 3) Beer TM. Progress in Prostate Cancer: An Update. Medscape <http://www.medscape.com/viewarticle/481669>, 2004.
- 4) Beer TM. Prostate Cancer at the 2004 Annual Meeting of the American Society for Clinical Oncology (ASCO) http://professional.cancerconsultants.com/conference_asco_2004.aspx?id=30936, 2004.
- 5) Beer TM. Management of Metastatic Prostate Cancer in a Nonelderly Patient With Comorbid Medical Conditions <http://clinicaloptions.com/onco/challenges/prostatecases/#beer>, 2005.
- 6) Beer TM. Treatment of a Patient With Metastatic Prostate Cancer and no Other Comorbidities <http://clinicaloptions.com/onco/challenges/prostatecases/#beer2>, 2005.
- 7) Beer TM. Prostate Cancer: Risk Factors, Prognostic Indicators, and Treatment Advances, Medscape CME, <http://www.medscape.com/viewprogram/4210> , 2005.

Reviews

- 1) Beer TM, Pierce WC, Lowe BA, and Henner WD. Docetaxel Weekly Administration in Symptomatic Androgen-Independent Prostate Cancer. Cancer Conference Highlights 4(12):2-5, 2000.
- 2) Beer TM and Bubalo JS, Complications of chemotherapy for prostate cancer. Seminars in Urologic Oncology, 19(3):222-230, 2001.
- 3) Hayes-Lattin BM, Maziarz RT, and Beer TM, Allogeneic stem cell transplantation in renal-cell carcinoma. Current Oncology Reports, 3(5):433-7, 2001.
- 4) Beer TM, Hough KM, Garzotto M, Lowe BA, and Henner WD. Weekly High Dose Calcitriol and Docetaxel in Advanced Prostate Cancer. Seminars in Oncology 28(4) Supp 15: 49-55, 2001.
- 5) Beer TM, Pierce WC, Lowe BA, and Henner WD. Weekly Docetaxel Treatment of Symptomatic Androgen-Independent Prostate Cancer. Advances in Prostate Cancer 6:8-10, 2002.
- 6) Beer TM and Bubalo JS. Docetaxel effects on pain due to androgen-independent prostate cancer. Current Urology Reports, 3:232-238, 2002.
- 7) Beer TM, Montalto MA, Lowe BA, and Garzotto M. High-Risk Localized Prostate Cancer Treated with Neoadjuvant Docetaxel and Mitoxantrone. Case Studies in Prostate Cancer, 1(2):2-7, 2002.
- 8) Hayes-Lattin BM, Kovach, PA, Henner WD, and Beer TM. Successful Treatment of Metastatic Hormone-Refractory Prostate Cancer with Malignant Pericardial Tamponade using Docetaxel. Review Series Oncology, 2:10-11, 2003.
- 9) Henner WD and Beer TM. A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in the Therapy of Prostate Cancer, Reviews in Urology, 5(S3):S38-S44, 2003. (PMCID: PMC1502349)
- 10) Beer TM. Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea. Health News, 9(8):1-2, 2003.
- 11) Beer TM. Chemotherapy for Androgen-Independent Prostate Cancer (AIPC). 2004 ASCO Educational Book pp. 225-232.
- 12) Beer TM. Experimental Use of GnRH Antagonists as Second-Line Hormonal Therapy. Reviews in Urology 6(Suppl 7):S33-S38, 2004 (PMCID: PMC1472888)
- 13) Beer TM, Myrthue A, and Eilers KM. Rationale for the Development and Current Status of Calcitriol in Androgen-Independent Prostate Cancer. World Journal of Urology, 23(1):28-32, 2005.
- 14) Oh WK and Beer TM. Current and Emerging Data on Novel Therapies in the Treatment of

Asymptomatic Prostate Cancer. *Oncology Consultations* 4(3):1-10, 2007.
15) Beer TM and Eisenberger MA. Integration of Findings from ASCO 2006 into Clinical Practice. Interactive CD-ROM program. 2007.

Invited Lectures, Conference Presentations or Professorships

International and National

2000

Multidisciplinary Approach to Prostate Cancer Frontiers of Medicine, Palm Springs, CA

2001

Medical Management of Prostate Cancer 69th APC, Loma Linda University, Loma Linda, CA

New Developments in Prostate Cancer 69th APC, Loma Linda University, Loma Linda, CA

The Medical Oncologist and Prostate Cancer Oncology Grand Rounds, University of Washington, Seattle, WA

Calcitriol and Docetaxel in the treatment of AIPC 2001 CaPCure Scientific Retreat, Lake Tahoe, CA

2002

Calcitriol and Docetaxel in AIPC 2nd International Prostate Cancer Congress, St. Thomas, VI

High dose calcitriol based therapy in prostate cancer treatment 2002 CaPCure Scientific Retreat, Washington, DC

Calcitriol based therapy for prostate cancer XXth Annual Chemotherapy Foundation Symposium, New York, NY

Calcitriol therapy for advanced prostate cancer 3rd Annual NCI/SUO meeting, Bethesda, MD

2003

Medical Management of Advance Prostate Cancer UCLA Oncology Grand Rounds, Los Angeles, CA

Medical Management of Advance Prostate Cancer West LA VA Oncology Grand Rounds, Los Angeles, CA

Aging and Prostate Cancer, Treatment of the Aging Patient with Cancer ASCO Satellite Symposium, Chicago, IL

Prostate Cancer and Aging, Geriatric Oncology Symposium, Los Angeles, CA

Vitamin D Receptor: A Novel Target in Prostate Cancer, New Paradigms in the Management of Prostate Cancer, Loyola University, Chicago, IL

Calcitriol based therapy for prostate cancer, Indiana University Grand Rounds, Indianapolis, IN

Advances in Strategies for prostate cancer, Loma Linda, CA

Emerging treatments for prostate cancer – Update on clinical trials, Monterey, CA

Androgen Independent Prostate Cancer: Standard treatment and the ASCENT Trial, San Francisco, CA

Vitamin D receptor as a target for prostate cancer therapy, Symposium, Western Section AUA, Las Vegas, NV

2004

Is Today's Chemotherapy Better Than Yesterdays' ICPC 2004, Whistler, Canada

Co-chair, Workshop on chemotherapy in prostate cancer ICPC 2004, Whistler, Canada

VDR – a novel target in Prostate Cancer Society of Urologic Oncology Annual Meeting, San Francisco, CA

Chemotherapy for Hormone Refractory Prostate Cancer, Systemic Therapy of Prostate Cancer: State of the Art (Educational Symposium at the 2004 ASCO Annual Meeting)

High-Dose Vitamin D as a Chemosensitizing Agent 4th International Prostate Cancer Congress,

Bermuda

Drug therapy for advanced prostate cancer. US Food and Drug Administration Seminar Series
Medical management of advanced prostate cancer. Grand Rounds, Los Angeles VA, Los Angeles, CA

Round Table Discussion: Challenges in the Treatment of Symptomatic Prostate Cancer Patients. Denver, CO

New development in the management of advanced prostate cancer. 8th Congress of the Polish Society of Clinical Oncology, Warsaw, Poland

Prostate Cancer Research. University of Colorado, Denver, CO

2005

Estrogen: A sheep in wolfe's clothing? Seminars in GU Oncology, Dana-Faber Cancer Institute, Boston, MA

Treatment and Approaches for Patients with High-risk Disease. Clinical Hematology and Oncology 2005!, Scripps Cancer Center, San Diego, CA

ASCENT: A double-blinded randomized study of DN-101 vs. placebo plus docetaxel in androgen-independent prostate cancer, 2006 ASCO, Chicago, IL

Prostate Cancer Oral Presentations, Session Chair, 2006 ASCO, Chicago, IL

Calcitriol ASCENT Trial, 4th International Symposium on Geniourinary Cancers, Los Angeles, CA

Practical Applications of new Agents in Genitourinary Malignancies, Practical Applications of New Agents in Oncology, San Antonio, TX

ASCENT: A double-blinded randomized study of DN-101 vs. placebo plus docetaxel in androgen-independent prostate cancer, ECCO, Paris, France

2006

Targeting the Vitamin D Receptor with High Dose Pulse Calcitriol, 13th International Workshop on Vitamin D, Victoria, BC

The place of systemic therapy in combined treatment of prostate cancer, "From the laboratory to clinical practice-Current perspectives in Oncology", Polish Society of Clinical Oncology/Polish Union of Oncology, Warsaw, Poland

What can we offer besides hormonal manipulations and chemotherapy, "From the laboratory to clinical practice-Current perspectives in Oncology", Polish Society of Clinical Oncology/Polish Union of Oncology, Warsaw, Poland

Intermittent Chemotherapy in Androgen-Independent Prostate Cancer, ASCO, Atlanta, GA

Best of ASCO Genitourinary Cancers, Best of ASCO, Beverly Hills, CA

Targeting the Vitamin D Receptor with High Dose Pulse Calcitriol, Prostate Cancer Congress, Boca Raton, FL

Targeting the Vitamin D Receptor with High Dose Pulse Calcitriol, Norway

The Case for AR-targeted therapy in AIPC, London, England

PSA-only androgen-independent prostate cancer: the condition and its natural history, Innovations and challenges in prostate cancer, Boston, MA

Vitamin D Receptor and Cancer Therapy, Emerging Strategies in Prostate Cancer Therapy, Prouts Neck, ME

Prostate Cancer Poster Discussion, Session Chair, 2006 ASCO, Atlanta, GA

2007

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial, 2007 Prostate Cancer Symposium, Orlando, FL

New Targets in Prostate Cancer, Session Chair and Discussant, 2007 Prostate Cancer Symposium, Orlando, FL

Novel Targets, New Options: Focus on the Nuclear Receptor VDR, American Society of Clinical

Oncology Satellite Symposium: "Improving Upon Current Standards: Integration of Novel Therapies in the Treatment of Androgen-Independent Prostate Cancer", Orlando, FL

Focus on Prostate Cancer, Hoag Cancer Center, Newport Beach, CA

Progress in Identifying Aggressive Prostate Cancer, American Association for Cancer Research, Los Angeles, CA

Targeting Vitamin D Receptor for Prostate Cancer Therapy, Dana-Farber / Harvard Cancer Center Vitamin D Symposium, Boston, MA

Timing of Taxane Administration in Androgen-Independent Prostate Cancer: When to Refer and When to Treat, American Urologic Association Annual Meeting: Society of Urologic Oncology Program, Anaheim, CA

Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC), ASCO Annual Meeting, Chicago, IL

Vitamin D Receptor and Prostate Cancer Therapy, Nevada Cancer Institute, Las Vegas, NV

Is androgen deprivation a benefit or a curse?, Geriatric Oncology Consortium: Advancing Cancer Care in the Elderly Conference, Washington, DC

Real World Settings, Real World Data: Management of Older Adults with Prostate Cancer, Geriatric Oncology Consortium: Advancing Cancer Care in the Elderly Conference, Washington, DC

2008

Management of Prostate Cancer, Hoag Cancer Center 4th Annual National CME Oncology Meeting, February, Newport Beach, CA

Annual Zoledronic Acid for Bone Loss Prevention, Genitourinary Cancers Symposium, February, San Francisco, CA

Medical Management of Docetaxel-Resistant Prostate Cancer, Genitourinary Cancers Symposium, February, San Francisco, CA

Androgen Independent Prostate Cancer, Challenging Cases in Urologic Oncology Conference, March, San Diego, CA

Managing Complications of Hormonal Therapy, Challenging Cases in Urologic Oncology Conference, March, San Diego, CA

Calcitriol in prostate cancer therapy, 3rd International Symposium: Vitamin D Analogs in Cancer Prevention and Therapy, May, Krefeld, Germany

Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC), 2008 ASCO Annual Meeting, June, Chicago, IL

Phase II study of first-line sagopilone combined with prednisone in patients with metastatic androgen-independent prostate cancer, 33rd ESMO Congress, September, Stockholm, Sweden

PANEL DISCUSSION: The Yin and the Yang of Ipilimumab for Prostate Cancer and Melanoma, Prostate Cancer Foundation 15th Annual Scientific Retreat, October, Lake Tahoe, NV

Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, Huntsman Cancer Institute, November, Salt Lake City, UT

2009

Quality of Life in Advanced Prostate Cancer: Management Strategies, Meet the Expert – Advanced Prostate Cancer, February, Orlando, FL

Prostate Poster Walk: Prostate Cancer, 2009 Genitourinary Cancers Symposium, February, Orlando, FL

2009 Oncology Clinical Debates in Prostate Cancer, Hoag Cancer Center Oncology Education Seminar, April, Newport Beach, CA

Phase II study of first-line sagopilone combined with prednisone in patients with metastatic

castration-resistant prostate cancer, 2009 ASCO Annual Meeting, May, Orlando, FL
Prostate Cancer in 2009, Mayo Clinic Medical Grand Rounds, June, Rochester, MN
Castration Resistant Prostate Cancer in 2009, 12th Congress of the Polish Society of Clinical Oncology, September, Sopot, Poland

2010

Chemotherapeutic Options in Castration-resistant Prostate Cancer: Optimizing Treatment Strategies, Duke School of Medicine and Medscape Oncology Online Continuing Medical Education Lecture Program, February, Webcast
Screening for Prostate Cancer in 2010, Hoag Cancer Center Oncology Grand Rounds, February, Newport Beach, CA
Community Oncology Clinical Debates in Castration-Refractory Prostate Cancer, Institute for Medical Education & Research 2010 Prostate Cancer CME Community Program, May, Sacramento, CA
Pain as an Endpoint: Relevance for this Patient Population, Prostate Cancer SATURN Study Investigators Meeting, May, Scottsdale, AZ
Poster Discussion: Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity, 2010 ASCO Annual Meeting, June, Chicago, IL
MDV3100 Phase I-II Trial in CRPC, PREVAIL North America Investigator meeting, September, San Francisco, CA
PREVAIL Critical Success Factors, PREVAIL North America Investigator meeting, September, San Francisco, CA
The Future of Oncology: Developing Personalized Medicine in Oncology, Elihu Root, M.D. Distinguished Lectureship Series at St. Lukes's Episcopal Hospital CME Internal Medicine Grand Rounds, October, Houston, TX
High Intensity Collaboration: An Essential Catalyst for Rapid Development of Novel Cancer Therapies, President's Cancer Panel: The Future of Cancer Research: Accelerating Scientific Innovation, October, Philadelphia, PA

Regional and Local

1999

Chemotherapy in Prostate Cancer ACS/Northwest Hospital Prostate Cancer Forum, Seattle, WA
Prostate Cancer in Native American Populations NW Tribal Cancer Control Proj. Clinician Training, Portland, OR

2000

Treatment of Advanced Prostate Cancer Oncology Nursing Society, Portland Chapter, Portland, OR
Neoadjuvant Therapy for Localized Prostate Cancer Oregon Urological Society Winter Meeting, Bend, OR
Hormonal Strategies for Advanced Prostate Cancer Oregon Urological Society Winter Meeting, Bend, OR
Role of Chemotherapy for Advanced Prostate Cancer Oregon Urological Society Winter Meeting, Bend, OR
The Emerging Role of Chemotherapy in Prostate Cancer St. Charles Hospital Tumor Board, Bend, OR
Management of Advanced Prostate Cancer Salem Hospital CRISP Conference, Salem, OR
Prostate Cancer Update for Primary Care Physicians 5th Ann. Specialties Update for Family Practice, Seaside, OR
Prostate Cancer, What's New Evergreen Hospital Grand Rounds, Kirkland, WA

Medical Management of Advanced Prostate Cancer Idaho Soc. of Clin. Oncology Annual Meeting, Sun Valley, ID

2001

Prostate Cancer Update 32nd Annual Family Practice Review, Portland, OR
Prostate Cancer Grand Rounds, North Bend Medical Center, Coos Bay, OR
Prostate Cancer at ASCO 2001 ASCO Review, Portland, OR
Multi-modality Therapy for High-risk Prostate Cancer 2001 Pacific Prostate Cancer Conference, Portland, OR
Clinical Trials in the Northwest 2001 Pacific Prostate Cancer Conference, Portland, OR
1 in 6 men will die of prostate cancer – what can we do about it? Grand Rounds, St. Charles Hospital, Bend, OR
Management of Androgen-Independent Prostate Cancer Tumor Board, St. Peters Providence Hosp., Olympia, WA

2002

Prostate Cancer Update 33rd Annual Family Practice Review, Portland, OR
Prostate Cancer at ASCO 2002 3rd Annual ASCO Review, Portland, OR
Endocrine therapy for prostate cancer Ashland Endocrine Conference, Ashland, OR
Treatment of Advanced Prostate Cancer Deaconess Hospital Tumor Board, Spokane, WA
What is the best treatment for localized prostate cancer? Benton County Med. Soc. Annual CME, Richland, WA
Chemotherapy in the treatment of advanced prostate cancer Pacific NW Prostate Cancer Conference, Seattle, WA
Innovative treatments in development in 2002 Pacific NW Prostate Cancer Conference, Seattle, WA

2003

Advances in Chemotherapy Strategies for Prostate Cancer, Eugene, OR
An Update on the Treatment Modalities and Clinical Trials for High Risk and HRPC Patients, Jacksonville, OR
Development of Calcitriol-Based Therapies for Prostate Cancer Univ. of Washington SPORE mtg., Seattle, WA
Advances in the Management of Advanced Prostate Cancer, IUN Series, Portland, OR
Medical Management of Advanced Prostate Cancer, Grand Rounds, SW Washington Med. Ctr, Vancouver, WA
Hormonal Therapy, Pacific NW Prostate Cancer Conference, Portland, OR
Current Research Initiatives in the Northwest, Pacific NW Prostate Cancer Conference, Portland, OR
New Developments in the Management of Advanced Prostate Cancer, Corvallis, OR

2004

Prostate Cancer Update, 35th Annual Family Practice Review, Portland, OR
A fresh look at prostate cancer, 11th Annual Internal Medicine Review, Portland, OR
Medical Management of Advance Prostate Cancer, OHSU Medical Oncology Grand Rounds, Portland, OR
Calcitriol in Prostate Cancer Therapy, 62nd Summer Lecture Series, Portland, OR
Aging and Prostate Cancer. OGEC Summer Institute, Portland, OR
Prostate Cancer Treatment. Cancer Control Training for the Indian Health Service
Development of calcitriol-based cancer therapy. Marquam Hill Lectures, Portland, OR
Prostate Cancer: What you need to know. Rotary Luncheon, Portland, OR

Chemotherapy and investigations therapies to treat advanced and metastatic disease, Pacific NW Prostate Cancer Conference, Seattle, WA

Current Research in the Northwest, Pacific NW Prostate Cancer Conference, Seattle, WA

Taxotere in the Management of Androgen-Independent Metastatic Prostate Cancer, Puyallup, WA

A multidisciplinary approach to prostate cancer, Sommer Memorial Lectures/OHSU Alumni Scientific Session, Portland, OR

2005

Evaluating Quality of Life: Clinical Trial Experience and Issues, Portland, OR

Prostate Cancer Training for the Latino Community, Portland, OR

Beyond Hormonal Manipulation: The Role of Chemotherapy for the Treatment of Advanced and High-risk Prostate Cancer, Spokane, WA

2006

Prostate Cancer: Willamette Falls Hospital Grand Rounds, Oregon City, OR

Advanced Prostate Cancer Survivorship Issues: Current immunotherapy and chemotherapy approaches, Pacific NW Prostate Cancer Conference, Seattle, WA

Breast and Prostate Cancer: Multidisciplinary Cancer Care for Women and Men, Portland, OR

2007

Advances in Prostate Cancer, Bend, OR

Advances in Prostate Cancer, Medford, OR

Prostate Cancer in 2007, Southwest Washington Medical Center Cancer Conference, Vancouver, WA

Prostate Cancer: When to Screen / When to Treat, 14th Annual Internal Medicine Review, Portland, OR

Prostate Cancer Research Program, OHSU Foundation Gift Planning Workshop, Portland, OR

Molecular Biology of Prostate Cancer, Graduate Cancer Biology Class, Portland, OR

Prostate Cancer Research Program, OHSU Foundation Planned Giving Council Meeting, Portland, OR

Advances in Prostate Cancer, Coos Bay, OR

Solving Prostate Cancer: The View from OHSU, 7th Annual Pacific NW Prostate Cancer Conference, September, Portland, OR

Updates in Prostate Cancer, OHSU Resident Noon Conference, Portland, OR

2008

Advanced Prostate Cancer, OHSU Hematology & Medical Oncology Fellows Grand Rounds, January, Portland, OR

What's New in Prostate Cancer, Meridian Park Hospital Primary Care Educational Conference, February, Portland, OR

Multidisciplinary cancer care, 2008 Payor Luncheon, April, Portland, OR

What's New in Prostate Cancer, Providence St. Vincent Internal Medicine Conference, April, Portland, OR

What's new in prostate cancer prevention and detection, OHSU Healthy Talks Community Lecture Series: Prostate Cancer Prevention, May, Portland, OR

Latest Advances from the OHSU Prostate Cancer Program, Advancements in Prostate Cancer Research and Care Luncheon, June, Portland, OR

The Prostate: More than a Gland, OHSU Department of Medicine Grand Rounds, September, Portland, OR

Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, Human

Investigations Program, November, Portland, OR
Evolving Multidisciplinary Management of Prostate Cancer, November, Portland, OR
Phase I Trial of Ipilimumab Alone and in Combination with Radiotherapy in Patients with Metastatic Castration Resistant Prostate Cancer, Northwest Urological Society's 55th Annual Conference, December, Portland, OR

2009

What's New in Prostate Cancer, 40th Annual Family Medicine & Primary Care Review, February, Portland, OR
Prostate Cancer Update, Salem Hospital's Department of Hematology Oncology, March, Salem, OR
Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, OHSU MSTP Grand Rounds, April, Portland, OR
Latest Advances in Prostate Cancer, Mahina Young's Golf Tournament, May, Aurora, OR
Systemic Therapy for Prostate Cancer in 2009, Evolving Multidisciplinary Management of Prostate Cancer Series, August, Bend, OR
The future of prostate cancer care, OHSU Prostate Cancer Support Group, September, Portland, OR
How we beat prostate cancer, 9th Annual Pacific NW Prostate Cancer Conference, September, Portland, OR
JOURNAL DISCUSSION: *Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer*, OHSU Prostate Cancer Journal Club, October, Portland, OR
Prostate Cancer in 2009, Indian Health Service Clinical Support Center's Clinicians Update Symposium, October, Portland, OR
How we beat Prostate Cancer, Ask the Health Experts lecture series, October, Portland, OR
Multidisciplinary care of prostate cancer, Evolving Multidisciplinary Management of Prostate Cancer Series, November, Seattle, WA
The future of oncology and the crucial contributions of surgery, OHSU Surgery Grand Rounds, November, Portland, OR
Progress in 2009 and a Vision for the Future, Advancements in Prostate Cancer Research and Care Program, December, Portland, OR
Multidisciplinary care of prostate cancer, Evolving Multidisciplinary Management of Prostate Cancer Series, December, Kennewick, WA

2010

Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, Linus Pauling Institute Seminar Program, January, Corvallis, OR
Prostate Cancer in 2010: New Data, New Controversies, 41st Annual Family Medicine & Primary Care Review, February, Portland, OR
Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, Achievement Rewards for College Scientists (ARCS) Foundation's Annual Meeting, March, Portland, OR
Systemic Therapy for Prostate Cancer in 2010, Novartis Hematology and Oncology Training Practicum, March, Portland, OR
Prostate Cancer in 2010: A focus on new developments, St. Charles Medical Center Grand Rounds Series, March, Bend, OR
Screening for Prostate Cancer in 2010, 17th Annual Internal Medicine Review, April, Portland, OR
PANEL DISCUSSION: *PSA Perspectives*, Oregon Urology Foundation's Annual Symposium: "Urology Update", April, Eugene, OR
The Future of Oncology, OHSU Hematology & Medical Oncology Grand Rounds, April, Portland, OR
Castration-Resistant Prostate Cancer in 2010, Salem Hospital and OHSU's 2010 Prostate

Cancer Symposium, April, Lake Oswego, OR
Advances in Prostate Cancer in 2010, OHSU Prostate Cancer Support Group, September, Portland, OR
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC), Portland Oncology Journal Club, September, Portland, OR
New Treatments on the Horizon, Ask the Health Expert Lecture Series, September, Portland, OR
New Treatments on the Horizon, 10th Annual Pacific NW Prostate Cancer Conference, October, Seattle, WA/Portland, OR
Cabazitaxel: A New Option for mHRPC Following a Docetaxel Containing Regimen Roundtable Program, Roundtable Program, November, Portland, OR
New agents changing the face of advanced prostate cancer, OHSU Hematology & Medical Oncology Grand Rounds, December, Portland, OR

Educational Activity:

Outpatient Clinic 1 ½ days per week. Frequently attended by Oncology fellows as well as Radiation Oncology and Internal Medicine Residents.

Housestaff Teaching Oncology conference (1-2/year), Noon conference (1/year), Department of Medicine Grand Rounds (0.5/year), Resident lectures (1/month)

Graduate Student Teaching Lecturer for Cancer Biology (CELL 616)

Direct Mentoring

National Level

I was invited to serve as a faculty mentor fellow sessions at the American Urological Association Annual Meetings in 2005 and 2007 and the 2007 Multidisciplinary Prostate Cancer Symposium. Faculty are selected from an international pool for their ability to mentor trainees as they contemplate a career in academic medicine.

2008 **Ilya Tsimafeyeu, M.D.**, Medical Oncologist, International Development and Education Award (IDEA) Program, Primary Mentor (Joshi Alumkal, M.D., Co-mentor). This is an international mentorship program sponsored by the American Society of Clinical Oncology

Institutional Level- Individual Mentorships

1999 **Rebecca Sunenshine, MD**, Clinical vignette Presentation, Oregon chapter of the ACP annual meeting, 1999

2001 **Emily R. Janega, BS**, in Biology (Reed College) theses entitled: $\alpha v\beta 3$ integrin expression in human prostate cancer

2001-2004 **Natasha Tiffany, MD**, Fellow in Hematology and Medical Oncology. Clinical research training. Dr. Tiffany developed two clinical trials under my supervision.

Peer reviewed manuscript: "Tiffany NM, Wersinger EM, Garzotto M, and

Beer TM. Imatinib mesylate and zoledronic acid in symptomatic androgen-independent prostate cancer. *Urology*, 63:934-939, 2004.”

Peer reviewed manuscript: “Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, and Beer TM. High Dose Pulse Calcitriol, Docetaxel, and Estramustine in Androgen-Independent Prostate Cancer (AIPC): A Phase I/II Study. *Journal of Urology*,174(3):888-92, 2005.”

Abstract: “Tiffany NM, Wersinger EM, Garzotto M, and Beer TM. Androgen-independent prostate cancer (AIPC) treatment with zoledronic acid and imatinib mesylate (STI-571). *Proc Am Soc Clin Onc* 22:421, 2003.”

Abstract: “Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High-Dose Calcitriol, Docetaxel, and Estramustine in Androgen-Independent Prostate Cancer (AIPC): A Phase I/II Study. *Proc Am Soc Clin Onc* 23:424, 2004.”

2001-2005 **Matthew Wagner, MD**, Urology Resident co-mentored with Dr. Garzotto in laboratory research (COX-2 expression and activity in prostate cancer). Received Rustin award for best medical student in Urology.

Peer reviewed manuscript: “Wagner M, Garzotto M, Lemmon D, Eilers KM, and Beer TM. Prostate Specific Antigen Decline after GnRH Antagonist Withdrawal in Androgen Independent Prostate Cancer. *Urology*, 65(4):799, 2005”

Peer reviewed manuscript: “Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM and Garzotto M. Resistance of Prostate Cancer Cell Lines to COX-2 Inhibitor Treatment *Biochem Biophys Res Commun*, 332(3):800-7, 2005.”

Abstract: “Wagner M, Weksler N, Loos J, Beer TM, Barry JM, Garzotto M. Cox-2 expression and effects of selective inhibition in prostate cancer cell lines.” Annual Northwest Urological Society Meeting. December 8, 2001.

Abstract: “Wagner M, Weksler N, Loos J, Beer TM, Barry JM, Garzotto M. Cox-2 expression and effects of selective inhibition in prostate cancer cell lines.” American Urological Assn Meeting, Abstract #542, 167:135, 2002.

2002 **Irene Panagiotou, MD**, Dr. Panagiotou did a 6-month research fellowship focused on outcomes research under my direct supervision

Peer reviewed manuscript: “Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, and Garzotto M. Predictors of Delayed Cancer-Directed Intervention in Patients Who Choose Watchful Waiting for Localized Prostate Cancer in the PSA Era, *Oncology (Basel)*, 67:194-202, 2004.”

Abstract: “Beer TM, El-Geneidi M, Panagiotou I, Peters L, Hsieh Y-C, Mori M, and Garzotto M, Delayed curative therapy in patients who initially choose watchful waiting in the PSA era. *J Urol* 169(4 Suppl):492, 2003

(Abstract 1844)”

Abstract: “Garzotto M, Panagiotou I, Hsieh Y-C, Mori M, Peters L, Klein T and Beer TM. Predictors of Delayed Prostate Cancer-Directed Intervention in Watchful Waiting Patients in the PSA Era. J Urol 169(4 Suppl):460, 2003 (abstract 1724)”

2002 - 2003 **Mohamed El-Geneidy, MD**, Dr. Elgeneidi is doing a 1-year research fellowship focused on outcomes research under my direct supervision

Peer reviewed manuscript: “El-Geneidy M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L, Klein T, and Beer TM. Delayed Therapy with Curative Intent in a Contemporary Prostate Cancer Watchful Waiting Cohort. BJU International, 93:510-515, 2004.”

Abstract: “Beer TM, El-Geneidi M, Panagiotou I, Peters L, Hsieh Y-C, Mori M, and Garzotto M, Delayed curative therapy in patients who initially choose watchful waiting in the PSA era. J Urol 169(4 Suppl):492, 2003 (Abstract 1844)”

Peer reviewed review: “Beer TM, El-Geneidi M, and Eilers KM. Docetaxel in the Treatment of Prostate Cancer. Expert Review of Anticancer Therapy, 3(3):261-268, 2003.”

2002 – 2003 **Lisa Bland, MD candidate** Ms. Bland was a senior medical student who has been awarded a 1-year research fellowship by the OHSU GCRC. She received the NL Tartar Fellowship, the SOM Research Award, Department of Urology Outstanding Medical Student, the William Krippaehne Outstanding Medical Student in Surgery Award for her work during 2002 year and 2nd place in resident poster competition at the Western Section of the AUA. She was mentored directly by me in this effort.

Peer reviewed manuscript: “Beer TM, Berry W, Wersinger EM, and Bland LB. Weekly docetaxel in the elderly: a comparison of efficacy and toxicity in prostate cancer patients age 70 and older and younger than 70. Clinical Prostate Cancer, 2:167-172, 2003.”

Peer reviewed manuscript: “Beer TM, Tangen C, Bland LB, Thompson IM, and Crawford ED. Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894. Journal of Urology, 172(6, Part 1 of 2):2213-2217, 2004.”

Peer reviewed manuscript: “Bland LB, Garzotto M, DeLoughery TD, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, and Beer TM. Phase II Study of Transdermal Estrogen in Androgen-Independent Prostate Cancer. Cancer, 103:717-23, 2005.”

Peer reviewed manuscript: “Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modifies memory in men, Journal of Urology, 175(1):130-5, 2006.”

Peer reviewed manuscript: "Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, and Beer TM. Effect of transdermal estrogen therapy levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. *Journal of Lipid Research*, 47(2):349-55, 2006."

Peer reviewed manuscript: "Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, Deloughery TG, Crawford ED. Prognostic Value of Hemoglobin Change After Initiation of Androgen Deprivations Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis Of SWOG 8894. *Cancer*, 107:489-96, 2006."

Abstract: "Bland LB, Tangen , Crawford ED, and Beer TM. Anemia Is An Independent Adverse Prognostic Factor in Untreated Metastatic Prostate Cancer: An Analysis of SWOG 8894. *Western Section of the AUA*, 2003."

Abstract: "Beer TM, Bland LB, Garzotto M, Ryan CW, Janowsky JS. Effect of High Dose Estrogen May Enhance Memory in Men with Prostate Cancer. *Proc Am Soc Clin Onc* 23:417, 2004."

Abstract: "Purnell JQ, Bland LB, Garzotto M, Lemmon D, Ryan CW, Beer TM. Transdermal Estrogen Therapy Improves Cholesterol Levels and Lipid Profiles in Men with Prostate Cancer. *Proc Am Soc Clin Onc* 23:734, 2004."

Abstract: "Bland LB, Tangen CM, Thompson IM, Crawford ED, Beer TM. Prognostic Value of Anemia in Untreated Metastatic Prostate Cancer: A Multivariate Analysis of SWOG 8894. *Proc Am Soc Clin Onc* 23:399, 2004."

Abstract: "Beer TM, Bland LB, Garzotto M, Purnell JQ, Ryan CW, Deloughery TG, Wersinger EM, Lemmon D. Transdermal estradiol in androgen-independent prostate cancer (AIPC). *Proc Multidisciplinary Prostate Cancer Symposium* 1:181, 2005"

Peer reviewed review article: "Lycette JL, Bland LB, Garzotto M, and Beer TM. The Case for Parenteral Estrogens for Prostate Cancer. *Clinical GU Cancer*, 5:198-205, 2006."

- 2002-2003 **Charlotte Wheeler.** MPH Candidate (2003) Thesis: "*Diabetes and time to recurrence of prostate cancer: A medical record linkage analysis*" I was a member of her thesis committee.
- 2003-2004 **Diane Chepa.** CURE Student (Summer Internship for underrepresented minorities in research) Direct mentor.
- 2003- **Eric Fromme, M.D.** (Assistant Professor of Medicine)
5K07CA109511-02 Systematic Approaches to Supportive Care in Prostate CA

Peer reviewed manuscript: "Fromme EK, Eilers KM, Mori M, Hsieh YC, and Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison to patient-reported symptoms from the QLQ-C30. *Journal of Clinical Oncology*, 22:3485-90, 2004."

Abstract: "Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM. How Good is Physician Reporting of Chemotherapy Adverse Effects? A Comparison to Patient-Reported Symptoms From the QLQ-C30. *Proc Am Soc Clin Onc* 23:730, 2004."

- 2003 - 2005 **Carrie Dul, M.D.** (Medical Oncology Fellow) Primary research mentor.
Project: "*Individually Tailored Dosing of Docetaxel in Geriatric Prostate Cancer Patients*" NIH grant submitted.
- 2003 - **Abdul Ahmet**, CURE program, Direct Mentor
- 2004 **Christopher T. Boniface**, summer college student (Direct Mentor)
- 2004 – 2006 **Jennifer Lycette, MD**, (Medical Oncology Fellow) Primary research mentor.
Peer reviewed manuscript: "Lycette JL, Luoh SW, Beer TM, and Deloughery T. Acute Bilateral Pulmonary Emboli Occurring While on Adjuvant Aromatase Inhibitor Therapy with Anastrozole – Case Report and Review of the Literature, *Breast Cancer Research and Treatment*, 99(3):249-55, 2006."

Peer reviewed review: "Lycette JL, Bland LB, Garzotto M, and Beer TM. The Case for Parenteral Estrogens for Prostate Cancer. *Clinical GU Cancer*, 5:198-205, 2006."
- 2004 – 2006 **Catherine O'Brien, MD**, (Medical Oncology Fellow) Primary research mentor.
Project: "*Characterization of human prostate cancer chemotherapy response using tissue microarrays*" in progress.

Abstract: "Nelson PS, Huang A, True LD, Garzotto M, Wersinger EM, O'Brien CA, Ryan CW, Ellis WJ, Lange PH, Higano CS, Beer TM. Molecular Correlates of Prostate Cancer Response and Resistance to Neoadjuvant Mitoxantrone and Docetaxel." InterProstate SPORE Meeting, Jan: 26, 2005.

Abstract: "O'Brien CA, Garzotto M, Higano CS, Wersinger EM, Kaimaktchiev V, Corles CL, Lange PH, Ryan CW, True LD, Beer TM. Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel. *Proc Am Soc Clin Onc* 23 (16S):408s, 2005"

Abstract: "O'Brien CA, True LD, Higano CS, Garzotto M, Takayama T, Ellis WJ, Lange PH, Katovic NM, Ryan CW, Beer TM. Histologic patterns in radical prostatectomy (RP) specimens of high-risk prostate cancer patients treated with neoadjuvant chemotherapy are predictive of nodal metastases. *Proc Prost Ca Symp* 2006"

Abstract: "O'Brien CA, Mongoue-Tchokote S, Collins L, Spurgeon S, Peters L, Beer TM, Mori M, Garzotto M. Assessment of PSA and digital rectal examination (DRE) for the detection of Gleason \geq 7 prostate cancer in a referral population. Proc Am Soc Clin Onc 24 (18S): 249s, 2006"

2004-2006 **Matthew Taylor** (Medical Student) Primary research mentor.
Project: "*Phase II Study of Xyotax in Advanced Prostate Cancer*" developed, funded and recently activated (see clinical trials)

2004- **Julie Graff, MD**, (Medical Resident)/(Oncology Fellow) Primary research mentor.

Abstract: "Graff J, Mori M, Li H, Garzotto M, Penson D, Potosky A, Beer TM. Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study. Proc Am Soc Clin Onc 24 (18S): 244s, 2006"

Peer reviewed manuscript: "Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky A, and Beer TM. Predictors of Overall and Cancer-Free Survival in Patients with Localized Prostate Cancer Treated Initially with Androgen Suppressive Therapy: Results from the Prostate Cancer Outcomes Study. Journal of Urology, 177(4):1307-12, 2007."

Abstract: "Graff J, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Predictors of overall (OS) and cancer-specific survival (CSS) in patients with clinically localized prostate cancer treated with primary androgen deprivation therapy: Results from PCOS. Proc Prost Ca Symp 2006."

2004-2007 **Joseph R. Bussiere** (MS candidate) Thesis advisory committee and co-mentor: "*The Effects of Testosterone Ablation on Verbal Memory Performance*"

Peer reviewed manuscript: "Bussiere JR, Beer TM, Neiss MB, and Janowsky JS. Androgen Deprivation Impairs Memory in Older Men, Behavioral Neuroscience, 119(6):1429-37, 2005."

Peer reviewed manuscript: "Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modifies memory in men, Journal of Urology, 175(1):130-5, 2006."

2005-2006 **Ryan Priest (MD Candidate)**
Project: Prostate DCE-MRI: Prostate Cancer Screening and Staging by Dynamic-Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) Pharmacokinetics

Manuscript: "Spurgeon SEF, Mongoue-Tchokote S, Collins L, Priest R, Hsieh Y-C, Peters LM, Beer TM, Mori M, Garzotto M. Assessment of Prostate-Specific Antigen Doubling Time in the Prediction of Prostate Cancer on Needle Biopsy, Urology, 69(5):931-5, 2007."

Manuscript: "Garzotto M, Mongoue-Tchokote S, Collins L, Priest R, Spurgeon S, Peters LM, Beer TM, Mori M. Nomogram For The Prediction Of Gleason \geq 7 Prostate Cancer in Men With a PSA of \leq 10 ng/ml. (in preparation)"

Abstract: "Garzotto M, Collins L, Priest R, Spurgeon S, Hsieh YC, Beer TM, Mori M. Nomogram for the prediction of high-grade prostate cancer on ultrasound-guided needle biopsy. Proc Am Soc Clin Onc 23 (16S):408s, 2005"

Abstract: "Spurgeon S, Garzotto M, Collins L, Priest R, Hsieh YC, Peters L, Beer TM, Mori M. Utility of PSA doubling time (PSADT) in the detection of prostate cancer in men with a serum PSA < 10 ng/ml. Proc Am Soc Clin Onc 23 (16S):408s, 2005"

2005-2007

Joe Chan, M.D. (Medical Oncology Fellow)

Protocol: "A phase II study of Paclitaxel Poliglumex(PPX) in Combination with transdermal estradiol for the treatment of androgen independent prostate cancer after docetaxel chemotherapy."

Abstract: "Chan JS, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether J, Chi KN, Young J, Shen C, Beer TM. Skeletal related events(SREs) in metastatic androgen independent prostate cancer(AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. (ASCO 2006)"

Abstract: "Chan JS, Lalani AS, Ryan CW, Berman C, Beer TM. C-Reactive Protein to Predict Risk of Skeletal Morbidity in Men with Androgen-Independent Prostate cancer: Results from the ASCENT Trial. (EUA 2007)"

Peer reviewed manuscript: "Chan JS, Beer TM, Quinn DI, Garzotto M, Sokoloff M, Dehaze DR and Ryan CW. A Phase II study of DN-101 (high-dose calcitriol) in combination with mitoxantrone and prednisone for androgen independent prostate cancer." (in preparation)

2006-2008

Ian Schnadig, M.D. (Medical Oncology Fellow), Primary Mentor

Prognostic Significance of Patient-Physician Disagreement About Performance Status in Patients with Advanced Cancer - poster discussion at ASCO 2007; manuscript underway

Comparison of Rescue Treatments for Breakthrough Chemotherapy-Induced Nausea and Vomiting - A Randomized Phase II Study - submitted for funding

Evaluation of C-reactive protein (CRP) and Other Serum Biomarkers as Predictor(s) of Performance Status, Chemotherapy Toxicity and Serious Adverse Events in Patients Receiving Docetaxel for Metastatic Androgen-Independent Prostate Cancer - statistical analysis underway

Pilot Study of a Treatment Algorithm to Manage Deferasirox-Associated Diarrhea - submitted for funding

Pregabalin for the treatment of chemotherapy-induced neurotoxicity - submitted for funding

Peer reviewed paper: Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM. Patient-Physician Disagreement About Performance Status Is Associated with Worse Survivorship in Patients with Advanced Cancer. *Cancer*, in press

Presented abstract: Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM, Perrin N. Prognostic significance of patient-physician disagreement about performance status in patients with advanced cancer. *Proc Am Soc Clin Onc: 25 (18S): 498s, 2007*

2006 -

Joshi Alumkal, MD (Assistant Professor), Junior Faculty, Primary Mentor (Mitchell Turker, co-mentor)

FAMRI Young Clinical Scientist Award: The Role of DNA Methylation as a Predictor of Biochemical Recurrence after Radical Prostatectomy and *NKX3.1* Gene silencing in Prostate Cancer: Importance and Mechanisms” 7/1/2006-6/30/2009

MRF: Epigenetic Therapies in Prostate Cancer: Identification of the Epigenome and Translation into Clinical Practice. 6/1/07-5/30/08

OHSU OSCR K12 Grant: Elucidation of Clinically Significant Gene Silencing Mechanisms in Prostate Cancer 4/1/07-

PROJECTS

1. *EZH2* and its role in the initiation of gene silencing in normal prostate cells- This project involved stable overexpression of *EZH2* *in vitro* followed by assessment of DNA methylation of genes known to be repressed transcriptionally by *EZH2* and which are also commonly found to have DNA methylation in human cancers in addition to the *NKX3.1* gene, which is commonly lost in prostate cancer through mechanisms independent of DNA methylation.

2. The effect of XB154, a small molecule inhibitor of *LSD1*, which turns on (AR) Androgen Receptor-regulated genes and represses tumor suppressor genes, on gene expression in prostate cancer using a candidate gene and genome-wide expression profiling with cDNA microarrays.

3. Impact of DNA Methylation on the Identification of Aggressive Prostate Cancer. This project involves the validation of a DNA methylation biomarker, which we previously found to be independently associated with an increased risk of prostate cancer recurrence.

- 2007 - **Christine Barnett, M.D.**
Vitamin D consumption and blood levels and risk of prostate cancer, an analysis of the MrOS cohort
- 2007 - **David Qian, PhD** (Assistant Professor), Junior Faculty, Primary mentor
Fred Hutchinson Cancer Research Center/Pacific NW SPORE \$65,000
(annual direct)
SPORE Career Development Award
9/1/07-8/30/08
- Medical Research Foundation \$29,936
Defining the role of histone deacetylase in bone-marrow mesenchymal stem cells response to prostate cancer bone metastasis
3/1/08-2/28/09
- 2007 - **Renee Prins, MD**, Resident.
Prognostic factors in prostate cancer.
- 2008 - **Faisal Siddiqui, B.S.**, Medical Student, Mentor
RSNA Research & Education Foundation, RSNA Medical Student Grant for Prostate DCE-MRI: Prostate Cancer Screening and Staging by Dynamic-Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) Pharmacokinetics
- 2008 - 2009 **Luke Fletcher**, Student, Murdock Scholar Program, Co-mentor
(David Qian, Ph.D., Co-mentor)
- 2008 - 2009 **Brinda Gokul**, High school student, Co-mentor (David Qian, Ph.D., Co-mentor)
- 2009 – 2010 **Marie Lafortune**, Student, Murdock Scholar Program, Co-mentor
(David Qian, Ph.D., Co-mentor)
- 2009 – 2009 **Elena De Jesus Hernandez**, High school student, Ted R. Lilley Cancer CURE Program, Co-mentor (David Qian, Ph.D., Co-mentor)

Institutional Level-Classroom Teaching

Medical Students Blood Pathophysiology small group instructor (2000 - 2005)
Biological Basis of Disease instructor (2001 – 2002)

Other AHEC MedStars Honors Program instructor (2001)
Human Investigations Program (HIP) lecturer (2002)
Monthly lectures on prostate cancer to rotating staff and students

Effectiveness of Educational Activity:

Along with this CV, I am enclosing evaluations of my OHSU Graduate Medical Education teaching and Continuing Medical Education teaching as well external Continuing Medical Education teaching. These evaluations provide strong evidence of the effectiveness of my teaching. My record of being invited and invited back to a broad range of teaching settings is perhaps provides real world evidence of my effectiveness. Consistent invitations to serve as a

discussant and/or lecturer at professional society annual meetings attest to the national recognition of my teaching skills. Talks at ASCO, AACR, SUO, Prostate Cancer Symposium, and others are routinely attended by 500 to 3,000 learners and featured on online access to annual meeting content. These are premiere venues at the largest international meeting in Oncology. Similarly, my strong record of attracting trainees to my clinical and research program provide evidence of effectiveness in this area.

Professional Development in Education:

I have honed my educational skills in several ways. “On the job training” has probably been the most important, although not formal, approach to professional development in education. I have lectured extensively and mentored an increasing number of trainees. Throughout these experiences, I have paid close attention to what works and what does not, carefully read my reviews, received direct feedback from trainees, and used this valuable information to continuously improve my performance.

Annually, I attend several national and international conferences that serve my professional development in education. ASCO, AACR, and AUA annual meetings are three flagship international meetings I attend regularly. In addition to scientific programs, these meetings offer a rich educational program. Regular annual attendance of these programs has allowed me to model my teaching after internationally recognized educators. Further, I have consistently attended sessions specifically devoted to professional development as an educator (sessions on mentoring etc). My efforts in this area have gained national recognition as illustrated by the invitation to deliver a major educational lecture at the 2004 ASCO meeting.

I have also gained expertise in obtaining educational funding by successfully securing NIH support for OHSU’s annual Prostate Cancer Conference.